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Abstract 
This literature review explored the question of which oral anticoagulant offers the best 
efficacy and safety for stroke prevention in non-valvular atrial fibrillation and how the nurse 
practitioner should select appropriate anticoagulation for these patients. The findings of this 
review demonstrate that warfarin remains a safe, effective and affordable therapy. 
Dabigatran, rivaroxaban and apixaban, offer an alternative for those patients that cannot 
tolerate warfarin, or who will benefit from their unique features, but further research is 
needed to address their limitations. The most appropriate therapy will depend on the 
individual context of each patient, and the nurse practitioner should assess all variables and 
discuss them with the patient before making a decision. Further research and surveillance are 
necessary to understand the role , use , side effects and impact of new oral anticoagulation in 
practice. This review offers recommendations that the nurse practitioner can apply to deliver 
care tailored to each patient. 
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CHAPTER I 
Introduction 
Atrial fibrillation (AF) is the most common chronic cardiac arrhythmia, with an 
incidence and prevalence that rises with age (Bashore, Granger, Hranitzky, & Patel, 2013) . It 
is estimated 350,000 Canadians are living with AF and that 15% of all strokes are caused by 
AF (Heart and Stroke Foundation, n.d.) . Ischemic stroke is the most serious consequence of 
AF, and it occurs due to stasis in the atria and consequent embolization, most devastating to 
the cerebral circulation (Bashore et al., 2013). The relative risk of stroke is 2-7 times that of 
patients without AF, with a rate of 5 events per 100 patient-years (Bashore et al.; Fuster, 
Ryden, Cannom, et al. cited in Wittkowsky , 2011). 
For over five decades , patients with non-valvular AF could only rely on warfarin 
therapy for oral anticoagulation and stroke prevention. Although highly effective, with a 64% 
stroke reduction (Hart, Pearce, & Aguilar, 2007) , warfarin therapy is inconvenient for clinical 
practice. It has a narrow therapeutic range and interacts with multiple medications and food, 
requiring regular international normalized ratio (INR) monitoring and dose adjustments . 
These issues frequently translate into low compliance and inadequate management of high-
risk patients in practice. Only approximate 50-60% of patients at moderate or high risk of 
stroke who are potentially eligible for anticoagulation with warfarin receive therapy (Go, 
Hylek, Borrowski , Phillips , Selby, & Singer, cited in Paikin, Hairon, & Eikelboom, 2011). 
Achieving adequate time in therapeutic range (TTR) is another challenge. A minimal 
target of 60% to 65 % of TTR is necessary for adequate and safe management of AF with 
warfarin, but such target can be difficult to achieve and contributes to the under utilization of 
warfarin in clinical practice (Conolly & Pogue et al., 2008; Hylek, Evans-Molina, Shea, 
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Henault, & Regan, 2007). Therefore news of novel oral anticoagulants was received with 
great enthusiasm by Canadian patients with AF and their health care providers. Direct 
thrombin (Factor Ila) and factor Xa inhibitors, offer a solution for the inconvenience of 
constant blood testing and dose adjustments that was necessary with warfarin , while offering 
other advantages such as faster onset of action, and potentially fewer adverse interactions 
(Mahtani , Heneghan, & Tai , 2012). 
Guidelines, such as the Canadian Cardiovascular Society (CCS) guidelines, and 
clinical recommendations were quickly updated to promote and encourage the use of these 
new drugs, but several controversies and questions also emerged, making the decision of 
which anticoagulant to choose not so simple (Sakanes et al. , 2012). As is the case with any 
new therapy in the market, drug interactions and adverse effects are still being monitored, 
and the real advantage in comparison with warfarin treatment remains to be seen in the real 
world . If that wasn 't enough, the lack of an antidote, in addition to the bleeding risk 
associated with anticoagulants , is enough to make prescribers reconsider their options before 
choosing these new therapies. 
Several serious concerns still need to be addressed. How can bleeding be managed in 
these patients and what are the risks we are willing to take? Similarly, there is no test to 
accurately and precisely monitor the intensity of the anticoagulation effect for these new 
drugs . Considering that the most important risk factor for hemorrhage in users of 
anticoagulants is the intensity of the anticoagulant effect (Levi, Eerenberg, & Kamphuisen , 
2011) , how do we ensure patients are within therapeutic range of treatment and not being put 
into unnecessary risk? Do the trials available provide enough evidence to support clinical 
superiority over warfarin or is this a simple matter of convenience of use and maintenance? 
What about the cost and patient compliance? Should those be factored when deciding which 
treatment is best? 
Even with all these questions lingering in the scientific community, the many 
advantages offered by these drugs have been enough to change guidelines and 
recommendations, and to produce a wide variety of opinions on scientific journals. This 
literature review was conducted to critically appraise this issue and offer specific 
recommendations to the nurse practitioner (NP) in primary care treating patients with non-
valvular AF. 
Nurse Practitioners and Atrial Fibrillation Management 
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NP practice focuses on diagnosing and treating diseases, disorders and conditions in 
the course of managing a client's health care (College of Registered Nurses of British 
Columbia [CRNBC], 2012). As primary (health) care providers, NPs also emphasize health 
promotion and disease and injury prevention (CRNBC, 2012). NPs diagnose and manage 
diseases , disorders and conditions within their scope of practice and individual competence 
within that scope of practice (CRNBC, 2012). They work with individuals, communities and 
diverse populations across the continuum of care based on principles of primary health care 
and contribute significantly to improve timely access to individualized, high-quality, cost-
effective care through a broad range of models of health care (Canadian Nurses Association 
[CNA], 2009). NPs play especially a key role in the management of chronic diseases, being 
involved in teaching , monitoring and adjusting therapies for this vulnerable group of patients . 
NPs in British Columbia manage, prescribe and work with patients with AF within the 
regulation and scope of practice as set out by the CRNBC (CRNBC, 2013). 
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NPs need to develop best practices for preventing complication in those with chronic 
illnesses and coach patients in healthy lifestyle changes that will minimize the risks and 
burdens of chronic illness (Anderson, 2009). As previously discussed, AF is one of the most 
common cardiac arrhythmias. With the growing number of elderly in Canada, it is expected 
that the number of patients living with AF will also increase dramatically (Heart and Stroke 
Foundation, n.d.). In fact hospital admissions for AF have increased by 66% over the past 20 
years due to an aging population and a rising prevalence of chronic heart disease (Friberg et 
al, 2003; Wattigney et al., 2003), and NPs will have a key role in the care of this population, 
offering education and appropriate therapy for these patients, which in turn will translate into 
fewer complications, such as strokes and disability. 
With the development of new oral anticoagulants, the NP will need to critically 
analyze not only the evidence that exists for each treatment option, but also contextualize it 
to each patient and his particular life circumstances, expectations, challenges and barriers. 
The decision-making process of the NP is rooted not only in the evidence available, but also 
in other variables that affect patient care, such as compliance, comfort, values and 
preferences. This project will analyze the evidence available in the literature by conducting a 
literature review, and offer recommendations for NPs to make an informed decision when 
choosing oral anticoagulant therapy in patients with non-valvular AF for the purpose of 
ischemic stroke prophylaxis in patients older than 65 years old, taking into consideration not 
only the pharmacologic actions of the medications and the evidence behind the benefits they 
claim, but also risk factors, cost, convenience and compliance. 
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Background and Context 
Atrial Fibrillation and Stroke 
AF is defined as a cardiac arrhythmia with the following characteristics (The Task 
Force for the Management of Atrial Fibrillation of the European Society of Cardiology 
[ESC], 20 I 0): the surface electrocardiogram (ECG) shows absolutely irregular RR intervals; 
there are no distinct P waves on the surface ECG; the atrial cycle length (i.e. the interval 
between two atrial activations) is usually variable and <200ms (>300 bpm) . AF can be 
symptomatic or asymptomatic and can occur in the absence of apparent cardiac disease. 
Nevertheless, it doubles death rates, independently of other known predictors of mortality 
(Kirchhof et al., cited in ESC, 2010). Risk factors include hypertension and coronary artery 
disease. Early signs and symptoms of AF include fatigue, palpitations, irregular rhythm, slow 
or rapid heart rate and syncope. 
Stroke is defined as an acute onset of a focal neurologic deficit of presumed vascular 
origin, from a non-traumatic cause, lasting for ~24 hours or resulting in death (Ezekowitz et 
al., 2009; Granger et al., 2011). A transient ischemic attack (TIA) in contrast, results in 
temporary neurologic deficit of presumed vascular origin, but without infarction. Strokes are 
classified as ischemic or hemorrhagic. Ischemic strokes result from a reduction in blood flow 
that lasts more than 4 or 5 minutes, and can be caused by atherothromboses, emboli , or 
hypoperfusion of the brain (Winland-Brown & Bedard, 2011). In contrast, hemorrhagic 
strokes are caused by intracranial bleeding, such as in an epidural or subdural hematoma, or 
in a subarachnoid and intraparenchymal hemorrhage (Winland-Brown & Bedard). 
AF can be caused by a variety of conditions as exemplified on Appendix A. AF that 
develops from rheumatic mitral valve disease, or from a procedure to repair or replace heart 
valves, is considered valvular AF. All other cases are considered non-valvular AF, and those 
will be the focus of this analysis. AF can be classified in 4 categories according to the 
Canadian Cardiovascular Society (CCS, 2010): 
First detected AF; 
Paroxysmal AF: self-terminating within 7 days of recognized onset; 
Persistent AF: not self-terminating within 7 days or terminated electrically or 
pharmacologically); 
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Permanent AF: cardioversion has failed or in which clinical judgment has led to a 
decision not to pursue cardioversion. 
The lifetime risk of developing AF is approximately 25 % in those who have reached 
the age of 40 (ESC, 2010). Furthermore, it is estimated that 6% of Canadians 65 years of age 
and older live with AF and that after age 60, one third of all strokes are caused by AF (Heart 
and Stroke Foundation, n.d .). Stroke risk in patients with AF increases from 1.5% in the fifth 
decade of life to 23.5 % in patients older than 80 years (Ogbonna & Clifford, 2013) . 
Considering the rapid ageing population in Canada, and the high prevalence of other 
comorbidities such as obesity , diabetes, and other chronic diseases , it is not surprising that 
stroke is the third leading cause of death in Canada according to the Heart and Stroke 
Foundation, and that stroke rates are on the rise. The necessity to manage the risk of ischemic 
stroke in AF is therefore paramount. 
Oral Anticoagulation in Atrial Fibrillation 
Up until 2010, warfarin was the only oral anticoagulant available in Canada for 
moderate and high risk patients, and despite its success in preventing strokes , it imposed 
many problems for clinical use . Frequent laboratory examinations and follow up consults , 
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impose a financial burden on the system and overall inconvenience to patients and their 
health care providers , as well as unacceptable risk of ischemic stroke during those periods 
when the patient is not within the therapeutic INR. A recent meta-analysis indicated that 
patients are only within therapeutic window approximately 55% of the time (Baker & Sander 
et al. cited in Littrell & Flaker, 2012) , leaving them vulnerable the rest of the time . 
The development of direct thrombin inhibitors and factor Xa inhibitors offer an 
alternative to all the issues faced with warfarin therapy. Nevertheless, some argue that 
caution is necessary, as it took over 50 years to learn how to use warfarin with reasonable 
effectiveness and safety for the prevention of strokes and the approval of certain oral 
anticoagulants is precipitated (Therapeutics Initiative, 2011) . Others take such drugs as a 
major advance in anticoagulant therapy, but acknowledge the limited data available to 
identify significant interactions, and conflicting interpretations of available evidence 
(Wittkowsky, 2011). NPs need to be aware of the evidence behind all the available therapies 
as well as their potential benefits and limitations in order to tailor care to their patient ' s 
needs. 
The coagulation cascade and pharmacotherapy. Normal homeostasis and 
hemostasis depends on blood fluidity and a balance between coagulation and fibrinolysis . 
Blood must remain fluid within the vasculature and yet clot quickly when exposed to 
subendothelial surfaces at the site of vascular injury (Weitz, 2011). Coagulation consists of a 
series of zymogen (or precursor protein) activation reactions, in which each zymogen is 
converted to an active protease by cleavage of one or more peptide bonds in the precursor 
molecule (Weitz, 2011) . Tissue factor (TF) is usually exposed when a vessel injury occurs. 
Factor VIla then binds to TF, creating the TF-factor VIla complex , which then activates 
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factors X and IX, initiating the coagulation cascade, culminating with the formation of 
fibrinogen and a blood clot. Appendix B illustrates the coagulation cascade activation leading 
to the formation of a thrombus. 
Oral anticoagulants act on different steps of the coagulation cascade to prevent clot 
formation . Direct thrombin inhibitors bind to and inhibit both soluble and clot bound 
thrombin , which is the most potent platelet agonist (Bereznicki & Peterson, 2010; Mahtani et 
al., 2012). This has the advantage of preventing feedback activation of factors V, VIII, and 
XI (Mahtani et al.). Direct thrombin inhibitors allow the blocking of thrombin activities as 
well as the prevention of fibrin formation from fibrinogen (Khoo & Lip, 2010). 
Inhibitors of factor Xa inhibit the formation of thrombin by binding directly to its 
precursor (Eriksson, cited in Mahtani et al., 2012). They are able to reversibly inhibit FXa 
when it is present in the prothrombinase complex, as well as when it is "free" (Bereznicki & 
Peterson, 2010). Factor Xa is an attractive target for anticoagulation because it acts as a 
convergence point of both the extrinsic and intrinsic coagulation pathway (Mann, Brummel, 
& Butenas, cited in Maan , et al., 2012). 
Warfarin inhibits the vitamin K epoxide reductase enzyme, which is essential for the 
production of coagulation factor II, VII, IX, and X. Therapeutic doses of warfarin decrease 
by 30-50% the total amount of each vitamin K-dependent coagulation factor made by the 
liver (Weitz , 2011), effectively interfering with the coagulation cascade and preventing 
thrombus formation. Warfarin is 99% bound to plasma proteins and is metabolized using 
cytochrome P450 (CYP450), which leads to significant drug interactions that can be caused 
by enzyme induction, inhibition, or decreased plasma protein binding (Trevor, cited in 
Thethi, Lewis , & Fareed, 2012). Furthermore, the gene encoding vitamin K epoxide 
reductase is subject to single-nucleotide gene polymorphism causing warfarin resistance 
(Trevor, cited in Thethi et al.). 
Risk stratification. The acute management of AF should concentrate on relief of 
symptoms and assessment of associated risks (ESC, 2010). Unfortunately not all patients are 
candidates for anticoagulation therapy because the risk of bleeding has to be carefully 
measured against the benefit of stroke prevention. Tools have been developed to assist with 
the risk stratification of patients and clinical decision making of when and who to treat. One 
of such tools - the HAS-BLED schema- has been created to help predict risk of bleeding 
(Appendix C) . A score is assigned on the presence of Hypertension, Abnormal liver or renal 
function, history of Stroke or Bleeding, Labile INRs, Elderly age (>65 years) and 
concomitant use of Drugs that promote bleeding or excess alcohol. Risk of major bleeding 
ranges from about 1% (score 0-1) to 12.5% (score 5) (Cairns, 2012) . 
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Many of the factors that determine stroke risk are also predictors of bleeding, but 
stroke risks usually exceeds those of major bleeding (Cairns , 2012a) . For example, a vitamin 
K antagonist, such as warfarin , will prevent approximately 30 strokes per 1000 patients 
treated for 1 year at a cost of at least 2 serious bleeding episodes per 1000 patient-years of 
treatment (Hankey , cited in Bereznicki & Peterson, 20 10). Furthermore, 70% of strokes with 
AF are fatal or leave severe residual deficits , whereas major bleeding is less often fatal and is 
less likely to leave significant residual effects in survivors (Cairns, 20 12a). 
Current recommendations state that for patients with AF, even when it is paroxysmal 
or occurs rarely, oral anticoagulation should be established and maintained indefinitely, if no 
contraindication to anticoagulation exists and if at least one risk factor for stroke is present 
(Bashore et al. , 2013; Camm et al. , 2012) . It is important for the NP to reassess risk 
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frequently, since patients that might not be eligible for anticoagulation initially, might later 
qualify for it. 
Table 1: The CHADS2 versus the 2009 Birmigham scheme (CHA2DS2- VASC) expressed as a 
point-based score system 
Risk factor Score for 
CHADS2 
Score for 
CHA2DS2-V ASC 
Congestive Heart Failure/ LV 1 1 
dysfunction 
Hypertension 1 1 
Age~ 75 1 2 
Diabetes Mellitus 1 1 
Stroke/ TIA/ TE 2 2 
Vascular disease (prior 0 1 
myocardial infarction, 
peripheral artery disease , or 
aortic plaque) 
Age 64-75 0 1 
Sex category (i.e. female 0 1 
gender) 
Source: Lip et al., (2010); Gage et al. (2004) .. LV= left ventricular; TIA= 
transischemic attack; TE= thromboembolism. 
The CHADS2 score is the most widely risk stratification scheme used in recent non-
valvular AF clinical trials to stratify stroke risk (Appendix D). The CHADS2 acronym was 
derived from the individual stroke risk factors in patients with atrial fibrillation: Congestive 
heart failure, Hypertension, Age> 75 years, Diabetes mellitus, and prior Stroke or TIA 
(Gage, Walraven, Pearce, Hart, Koudstaal, Boode, & Petersen, 2004). Two points are given 
for prior stroke or TIA (hence, the subscripted "2"), and 1 point is assigned for each of the 
other factors. More recently, authors have been advocating for the use of the Birmingham 
2009 system (CHA2DS2-V ASC) , which was found to be more specific than the CHADS2 in 
stratifying those at risk for thromboembolism (Cairns, 2012a; Lip, Nieuwlaat, Pisters, Lane, 
Harry, & Crijns, 2010). Nevertheless, all the randomized controlled trials (RCTs) available 
for the novel oral anticoagulants have still used the CHADS2 criteria to help categorize their 
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patient population. Table 1 summarizes the score for the CHA2DS2-VASC versus the 
CHADS2 criteria. 
Unfortunately , only about half of the patients with indications for oral anticoagulation 
are receiving it, and they are out of the targeted INR for nearly half of the time (Bashore et 
al., 2013) . The necessity of safe and efficient alternatives to warfarin is therefore clear and 
the NP is in a key position to provide access to adequate treatment to patients with AF, 
tailoring each therapy to the specific context of each patient, creating immeasurable impact in 
the future quality of life of such patients . 
Clinical Judgment and Pharmacotherapy 
Prescribing a treatment is not just a matter of choosing which drug is the best; but 
which one is the most appropriate for a specific patient in one specific context. The selection 
of an anticoagulant should be made based on the absolute risk of bleeding, and the relative 
risk and benefit for a given patient (Littrell & Flaker, 2012) among other variables. The final 
decision reached by the prescriber is not one made on clear objective variables. It involves 
the context (social , political and economical), the patient (beliefs and assumptions, 
willingness to follow treatment), the prescriber (experience, intuition, and knowledge) and 
the scientific evidence (clinical trial results , side effect profile, interactions with other 
medications and safety). For example, for some patients the financial costs of two 
comparable treatments might be an important factor. For others, the idea of less office visits 
and laboratory trips might be worth the risk of trying a new therapy. Similarly, for NPs, 
seeking patient compliance with treatment might steer decisions in one direction versus the 
other, as well as published guidelines , or their own experience and intuition with different 
patients and different treatments . 
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It is also important to consider the unique context of primary care. As per the Institute 
of Medicine (IOM) definition, primary care is the provision of integrated, accessible health 
care services by clinicians who are accountable for addressing a large majority of personal 
health needs, developing a sustained partnership with patients and practicing in the context of 
family and community (IOM, cited in Anderson & O'Grady, 2009). The NP in primary 
health care has the unique advantage and opportunity to coordinate care and influence patient 
outcomes. This is especially true for the management of chronic illnesses such as AF. Using 
a holistic approach to assessment and treatment, the primary care NP addresses illness, 
promotes health, and prevents disease, while developing trusting relationships through strong 
interpersonal skills, patient and family education, and coaching and guidance (Anderson & 
O'Grady, 2009). 
The aim of this literature review is to create recommendations to NPs practicing in 
primary care in regard to the clinical decision making when choosing appropriate prophylaxis 
for stroke in patients with AF using oral anticoagulants, namely warfarin, dabigatran, 
apixaban, and rivaroxaban. The recommendations offered in this review will allow the NP to 
improve care, management and access to treatment for patients living with AF. The adequate 
management of AF in primary care translates in improved quality of life, increased 
compliance, improved health outcomes and less complications. It also impacts the health 
care system as whole, which otherwise has to absorb the care and cost imposed by a 
devastating event such as a stroke. The following session will describe the methods utilized 
in this review of the literature. 
CHAPTER II 
Methodology 
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Integrated reviews are conducted to identify, analyze, and synthesize the results from 
independent studies to determine the current knowledge in a particular area (Beya & Nicoll, 
cited in Burns & Grove, 2009). This review involved the following stages 1) development of 
the research question, 2) development of search strategy, 3) focused search, and 4) analysis 
and reporting. 
Development of the Research Question 
My personal interest in the management of chronic disease, and of cardiac disease in 
particular, has driven me to investigate the issue of anticoagulation in cardiac disease further. 
I was intrigued with the news of new oral anticoagulants that solved all the issues we had 
with warfarin . In order to focus my question and literature search further, I narrowed my 
study population to patients with AF >65 years old , since this is one of the largest groups that 
could benefit from oral anticoagulation. I positioned my question in the context of the NP 
working in primary care. A PICO (population, intervention, comparator and outcome) 
question was then formulated and a literature review conducted as suggested in DiCenso, 
Guyatt, and Ciliska (2005) as following: 
1. PICO question formulated (Figure 1); 
2. Literature search conducted as described below; 
3. Inclusion and exclusion criteria applied; 
4. Data abstracted. 
5. Analysis conducted 
Figure 1: P .I.C.O. question 
• 
• 
• 
• 
Population: Adults >65 years old with non-valvular atrial fibrillation 
Intervention: Treatment with direct thrombin inhibitors or Factor Xa inhibitors 
Comparator: Treatment with warfarin 
Outcome: Stroke 
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The main question proposed for this review is: What is the most appropriate therapy 
for stroke prevention in AF in a primary care setting? The following questions were 
formulated to guide the search: what should the NP in primary care consider when choosing 
appropriate anticoagulation therapy for patients with non-valvular AF and how do direct 
thrombin inhibitors and Factor Xa inhibitors compare to warfarin for stroke prevention in 
AF? 
These questions were designed to guide the literature search, but this review did not 
conduct a purely quantitative analysis of the data, but rather a qualitative one. For example, 
literature was reviewed to assess if the measured benefits of a drug regimen (such as number 
of side effects , risk reduction) are comparable to the social disadvantages of it (cost, 
convenience , comfort). Additionally , the context of the research studies were examined to 
identify if a specific therapy may offer an advantage over another in particular population 
group or within a given context. Taking this qualitative lens, in addition to the methods 
typically used in a review , can help consider the important contextual insights that are 
relevant for the NP when deliv~ring patient-centered care. 
Search Strategy 
The search was designed to identify current and relevant guidelines, systematic 
reviews and primary research studies. The first step comprised of the formulation of a 
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conceptual map to assist with developing the appropriate search terms (see Figure 2) . From 
this map, each concept was broken down into searchable and related concepts. The 
following search words were identified: atrial fibrillation; anticoagulants; warfarin; factor Xa 
inhibitor; factor IIa inhibitor; vitamin K antagonist; apixaban; dabigatran , rivaroxaban; direct 
thrombin inhibitor; stroke; and stroke prevention. 
Figure 2: Concept map utilizing the P.I.C.O.framework 
r " r ""' Population: Adults Intervention: treatment 
diagnosed with atrial with oral anticoagulants/ 
fibrillation/ Nurse .... decision making when ,. 
Practitioners in primary prescribing treatment 
care 
\... ..J \. ..J 
" r " r " 
Outcome: stroke prevention 
Comparison: warfarin, 
direct thrombin inhibitors 
I choice of adequate oral ~ (dabigatran), factor Xa 
anticoagulant " inhibitors (rivaroxaban, 
apixaban). 
\.. ..,I \. ~ 
Search terms were used separately or in combinations using AND/OR in Boolean 
search mode (See Table 2). Appendix E illustrates the literature search process and the results 
obtained. The following electronic databases were searched in English , from 1985 to 2013: 
the Cumulated Index of Nursing and Allied Health Literature (CINAHL); the Cochrane 
reviews and Medline. The Internet was searched for relevant organizations that publish 
guidelines for AF management, utilizing the Google Internet search tool. 
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Table 2: Detailed database search results 
Database 
Keywords CINAHL MEDLINE COCHRANE 
1. Atrial fibrillation (exp.) 6220 3363 4007 
2. Anticoagulants (exp.) 3497 186725 4154 
3. Warfarin (exp.) 1911 14456 2303 
4. Factor Xa inhibitor (exp.) 56 4486 160 
5. Coumarins (exp.) 78 39886 173 
6. Apixaban 119 530 92 
7. Dabigatran or dabigatran 355 1552 153 
etexilate 
8. Rivaroxaban 14 976 154 
9. Stroke (exp.) 21957 84114 21228 
10. Stroke prevention 4508 3236 767 
11. 1 or 2 or 3 or 5 10374 226813 8687 
12. 9 or 10 23568 85042 21228 
13. 4 and 11 and 12 8 137 25 
14.6 and 11 and 12 49 214 38 
15. 7 and 11 and 12 91 550 72 
16. 8 and 11 and 12 5 234 42 
17. 3 and 11 and 12 305 1520 624 
N= 13+ 14+ 15+ 16+ 17 458 2655 801 
Inclusion criteria. Titles and abstracts were then analyzed to determine relevance. 
Only articles in English, published in peer-reviewed journals, or guidelines from accredited 
institutions that apply to adults, and studies relevant to the Canadian health care context were 
selected. Articles that focused on therapeutic management of AF and that were published in 
17 
the last 5 years were selected. Title and abstracts were previewed and articles directly 
comparing oral anticoagulants, as well as all existing controlled trials of direct thrombin 
inhibitors and factor Xa inhibitors were searched and retrieved for critical analysis. Other 
titles with expert reviews, opinions and analysis were included. From the resources obtained, 
relevant articles from reference lists were also retrieved and included. 
Exclusion criteria. Studies that could not be accessed through the University of 
Northern British Columbia library or with links that were not working were excluded. Also 
excluded were articles focusing on a different populations (such as coronary artery disease 
and venous thromboembolism), different drug therapies or populations younger than 19 years 
old. 
Focused search. Following the initial identification of literature, a focused search 
was undertaken. This involved screening of the abstracts , removing duplicates, and 
crosschecking sources through a review of reference lists and guidelines. During this, a final 
cohort of 134 papers was selected for inclusion in this review. 
Analysis and Reporting 
Data was extracted and critically appraised from the final cohort of 134 articles. Each 
article was critically appraised for methodological quality and scientific merit. Three new 
oral anticoagulants approved for clinical use were identified: dabigatran, rivaroxaban and 
apixaban . All phase III RCTs available were critically appraised and the results summarized. 
Similarities and heterogeneities of the compared studies were identified and summarized. A 
synthesis of the identified therapeutic modalities, advantages and disadvantages , in relation to 
the patient and clinician context and decision-making process was conducted to generate 
recommendations for decision making for NPs when prescribing oral anticoagulants in 
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primary care. The findings were further divided into two main categories: Pharmacological 
management and Clinical decision-making. The first category discusses the clinical data 
available and critically appraises the RCTs for dabigatran, rivaroxaban and apixaban . The 
second category utilized the data from the RCTs to consider implications for NP practice, 
pulling specific recommendations for eleven themes that were identified as relevant for 
decision-making: 1) risk, 2) demographics , 3) cost, 4) adherence, 5) safety and side-effect 
profile, 6) drug-drug and food interactions, 7) anticoagulation reversal, 8) renal impairment, 
9) age , 10) coronary artery disease, and 11) other limitations. 
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CHAPTER III 
Findings 
This chapter explores, discusses and critically analyzes the data and evidence 
available for the use of new oral anticoagulants in AF for stroke prevention , contrasting it 
with the use of warfarin, while discussing the outcomes and limitations associated with each 
treatment. As previously discussed, stroke is the most significant morbidity in patients with 
AF (Lopes et al., 2010) . Approximately 15% of strokes occur in those with AF and the risk 
of stroke in untreated patients averages 5% per year (Benjamin et al. cited in Lopes et al. , 
2010). 
This section presents the findings encountered as a result of the literature review 
conducted to assist the NP in primary care in deciding appropriate oral anticoagulation for 
patients with AF. The analysis presented here offers relevant insight into the evidence 
available to the NP. All the available phase III randomized controlled trials were discussed 
and critically appraised. Following the analysis, the data was divided into two major 
categories: pharmacological management and clinical decision-making. The first category, 
pharmacological management, explores the characteristics of each new oral anticoagulant 
and the evidence that supports its use in AF. The second category , implications for clinical 
practice, identified special considerations that the NP needs to include and consider in the 
decision-making process, and was subdivided into 11 subcategories: 1) risk , 2) 
demographics , 3) cost, 4) adherence , 5) safety and side-effect profile , 6) drug-drug and food 
interactions , 7) anticoagulation reversal, 8) renal impairment, 9) age, 10) coronary artery 
disease, and 11) other limitations. These categories will now be discussed. 
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Pharmacological Management 
Therapeutic management is one of the most complex decisions the NP needs to make 
in primary care. Appropriate therapeutic management depends on multiple variables; some 
associated to the drug itself, and others the context in which treatment is being initiated. With 
the introduction of direct thrombin inhibitors and factor Xa inhibitors, the range of 
therapeutic options available for the treatment of AF has increased considerably, and the NP 
will need to be familiar with the advantages and disadvantages of each treatment, as well as 
the limitations and the strength of the evidence behind the data in order to make an 
appropriate decision tailored to the individual needs of each patient. In this section, a critical 
evaluation of the literature related to the key pharmacological therapies is presented, 
including a review of dabigatran, rivaroxaban and apixaban as they compare to warfarin 
Dabigatran. Dabigatran was the first new oral anticoagulant approved by Health 
Canada in 2010 for the prevention of stroke and systemic embolism in patients with AF, in 
whom anticoagulation is appropriate (Boehringer Ingelheim Canada, 2012). To contextualize 
this, a brief overview of the pharmacological action is presented following a critical review 
of the key clinical trials and research studies. 
Pharmacology. Dabigatran etexilate is an oral prodrug that is rapidly converted by a 
serum esterase to dabigatran, a potent, direct, competitive inhibitor of thrombin (Connolly et 
al., 2009). It directly inhibits free and clot-bound thrombin therefore inhibiting clot formation 
as well as thrombus expansion (Paikin et al. , 2011). It is dosed as 110mg or 150mg BID and 
it has a relatively short half-life of 8-1 Oh and 14-17h for single and multiple-dose 
administrations, respective! y, in patients with normal kidney function. 
A major advantage over warfarin is that dabigatran does not require regular 
laboratory monitoring, due to its predictable pharmacodynamics , and its actions are not 
influenced by dietary habits. It has a more predictable anticoagulant response than warfarin 
with fewer drug-drug interactions (Paikin et al., 2011). Dabigatran is mostly excreted 
unchanged by the kidneys (80%), and it has a bioavailability of 6.5% (Khoo & Lip, 2010). 
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Clinical trials. To date there is only one phase III randomized controlled trial (RCT) 
of dabigatran for stroke prevention in non-valvular AF: the randomized evaluation of long-
term anticoagulant therapy warfarin , compared with dabigatran (RE-LY) trial (Connolly et 
al., 2009; Eikelboom et al., 2011; Ezekowitz et al., 2009). Even though the RE-LY trial was a 
large and well-designed phase III , multicenter, prospective, open-label, randomized trial with 
blinded evaluation of all outcomes, it is still the only phase III RCT available, it was open 
label and surrounded by controversies . This study will now be discussed. 
The RE-LY compared the safety of two doses of dabigatran (110mg and 150mg twice 
a day) against warfarin (titrated to a therapeutic INR of2-3.0), for the primary outcome of 
stroke or systemic embolism in 18,113 patients with AF followed by 2 years (Connolly et al., 
2009). The mean age of the participants was 71 years with an average CHADS2 score of2 .1 
(Connolly et al.). The primary safety outcome was major hemorrhage. Secondary outcomes 
were stroke, systemic embolism, and death. 
Patients evaluated in this study had AF and at least one other risk factor for stroke 
such as: previous stroke or TIA or systemic embolism; left ventricular ejection fraction <40% 
or symptomatic heart failure; hypertension; age> 75 years; or age 64-74 years with either 
diabetes mellitus or coronary artery disease (Connolly et al., 2009) . In order to be considered 
as AF, a patient needed to have documented AF on the day of screening or randomization; or 
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a symptomatic episode of paroxysmal or persistent AF documented by 12-lead ECG; or 
documentation of symptomatic or asymptomatic paroxysmal or persistent AF on 2 separate 
occasions (Ezekowitz et al. , 2009). 
Findings. Following a comparison of dabigatran and warfarin, both doses of 
dabigatran were noninferior to warfarin, with ap value <0.001 (Connolly et al., 2009). The 
150mg dose of dabigatran was found to be superior to warfarin with a relative risk (RR) of 
0.66 (95 % confidence interval [CI] [0 .53, 0.82],p < 0.001) (Connolly et al., 2009), and an 
absolute risk reduction (ARR) of 0.58%. 
For the principal outcome of stroke or systemic embolism, rates were 1.69%/year 
with warfarin, 1.53%/year with dabigatran 110mg (RR .91; 95 % CI [0.74, 1.11]) , and 
1.11 %/year with dabigatran 150mg (RR 0.66; 95% CI [0 .53 , 0.82]) (Connolly et al. , 2009). 
Considering that the risk of stroke on warfarin is already low, an ARR of0 .58% with 
dabigatran 150mg might translate into 1-2 less strokes, depending on number of patients 
treated and the time. Nevertheless, when we are talking about such a devastating primary 
outcome as stroke, such reduction can still be clinically significant as long as the associated 
risk of bleeding is acceptable. 
The rates of hemorrhagic stroke were 0.38% per year in the warfarin group , versus 
0.12% with of dabigatran llOmg , and 0.10% per year in the group that received 150 mg of 
dabigatran (Connolly et al., 2009), which translates into an ARR of0.26% with dabigatran 
llOmg and 0.28 % with dabigatran 150mg. The risk of major bleeding overall was higher in 
the warfarin group: 3.36% per year, as compared with 2.71 % per year with dabigatran 110mg 
(RR with dabigatran , 0.80; 95 % CI [0.69, 0.93]; p = 0.003) and 3.11 % per year with 
dabigatran 150mg (RR, 0 .93; 95% CI [0.81 , 1.07]; p = 0.31) (Connolly et al., 2009). This 
means that in the RE-LY trial, dabigatran 150mg demonstrated better outcomes than 
warfarin, with a safer profile in relation to intracranial bleeding and major bleeding 
(Connolly et al. , 2009) . Dabigatran 150mg was more effective for stroke prevention than 
dabigatran 110mg across all ages (Connolly et al.) 
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In a subset analysis of patients with a previous stroke or transient ischemic attack 
(TIA) undertaken by the investigators of RE-LY, dabigatran 150mg showed noninferiority to 
dose-adjusted warfarin in patients with a CHADS2 ~3. and dabigatran 110mg reduced the 
risk of major bleeding compared with warfarin (RR 0.66, 95% CI [0.48, 0.90]). The rate of 
intracranial bleeding was significantly lower with both doses of dabigatran (110 mg 0.25 % 
per year, RR 0.20; 95 % CI [0 .08, 0.47]; 150 mg 0.53 % per year, RR 0.41, 95% CI [0.21-
0.79]) than with warfarin (1.28% per year) (Lane & Lip, 2010). Some authors claim that 
dabigatran 110mg is a better option for this group of patients due to its reduced overall 
bleeding complications compared to warfarin (Panichpisal et al. , 2011), but the investigators 
of RE-LY could not conclude that there was a true benefit on mortality with the 110 mg dose 
compared with warfarin on their report , because there was no significant interaction between 
death from any cause and previous stroke or TIA (Diener et al., 2010). Their final conclusion 
was that in patients with previous stroke or TIA, 150 mg dabigatran might provide better 
protection against stroke than warfarin, whereas 110 mg dabigatran is as efficacious as 
warfarin and reduces adverse events (bleeding complications and mortality in comparison to 
warfarin) (Diener et al. , 2010) . 
Another posthoc subset analysis was undertaken in patients being cardioverted. 
Cardioversion is undertaken to restore sinus rhythm in patients with AF and can take the 
form of pharmacological agents (such as amiodarone) or electrical (such as direct current 
24 
cardioversion/ablation therapy). The investigators identified that stroke, systemic embolism 
and major bleeding rates after cardioversion were low in both the dabigatran and warfarin-
assigned groups (N agarakanti et al. , 20 11). The use of transesophageal echocardiogram 
(TEE) was higher in patients assigned to dabigatran compared with those assigned to 
warfarin , as well as the concomitant use of antiplatelets such as aspirin and clopidrogel, 
which could have introduced bias in the results. Investigators argue that stroke and systemic 
embolism rates were similar for both conventional and TEE-guided cardioversions, 
suggesting that cardioversion could be performed on patients on dabigatran regardless of the 
use of TEE (N agarakanti et al., 2011). 
Translating the data. To understand these statistics better, imagine treating for one 
year a population of 1,000 patients with non-valvular AF and the same demographics of 
patients as the trial participants. What RE-LY has showed is that if that group was treated 
with warfarin, we could expect 12 ischemic strokes and 4 hemorrhagic strokes. If those same 
patients were treated with dabigatran 110mg instead, we could expect 1 extra ischemic stroke 
but 3 less hemorrhagic strokes. If treated with dabigatran 150mg, we would probably see 3 
less ischemic strokes and 3 less hemorrhagic strokes than warfarin (see appendix G) . This 
analysis demonstrates that dabigatran 150mg seems to be more efficient in preventing 
ischemic strokes with a better safety profile, while dabigatran llOmg is as effective as 
warfarin but safer. 
Nevertheless, there are several other aspects that need to be explored. When 
analyzing the RE-LY data, one observes that the patient is at increased risk of an intracranial 
bleed with warfarin treatment (0 .76% vs 0.32% with dabigatran 150mg), but increased risk of 
GI bleed with dabigatran . The high concentrations of active drug in the colon could explain 
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the increase in GI bleeding with the higher dose of dabigatran, due to an increased local 
antihemostatic effect (Paikin et al. , 2011). Most importantly is that in both cases, the number 
of events is very low , including fatalities due to any cause (4.13% for warfarin; 3.75% for 
dabigatran 110mg; and 3.64% for dabigatran 150mg). There was also an increased risk of 
dyspepsia in the dabigatran group, which may lead to drug discontinuation or 
noncompliance , and a reduction in effectiveness (Paikin et al., 2011). These are all important 
considerations for the NP and will be discussed in further detail in the section of clinical 
decision-making. 
Dabigatran post market. Shortly after the FDA approved dabigatran for clinical use, 
reports of increased bleeding events in patients taking the drug were filed . The agency 
conducted a post market safety review , concluding that the bleeding rates were comparable to 
those associated with new users of warfarin, and similar to what was reported in RE-LY 
(FDA, 2012) . 
A post market cohort study conducted in Denmark, assessed the efficacy and safety in 
an 'everyday clinical practice' population of patients with AF treated with dabigatran (Larsen 
et al., 2013). Although encouraging, the results of this study should be taken with 
considerable caution. It was done based solely on data from the Danish prescription, civil and 
national patient databases. These databases were not developed for the purpose of the study, 
and therefore , the lack of direct patient observation could have resulted in important signs 
and symptoms being ignored in the final results. Also, this study assumed the answer for two 
important questions: it was assumed that the dabigatran and warfarin treatment period was 
initiated at time of diagnosis ; and treatment was assumed to be lifelong, and hence treatment 
was assumed to end only if a prescription of an alternative was registered (Larsen et al.). The 
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report of no patients lost to follow up is questionable, since a patient could just have stopped 
taking the medication and not be placed on any other anticoagulant, yet be assumed to be still 
taking the drug. 
Although the power of this study was very good (80%), it was relatively short (only 
10.5 months), which still leaves the question about the long-term use of dabigatran in AF 
unanswered. Also, when compared with the RE-LY study, the population of the Danish study 
had an overall lower stroke risk (mean CHADS2 score of 1.16 vs RE-LY 2.13) and less 
comorbidities (Larsen et al. , 20 13). Despite its limitations, the results of the Danish cohort 
study were encouraging in finding results similar to the RE-LY trial. Rates of stroke were not 
significantly different between warfarin and dabigatran treated patients, but adjusted 
mortality was lower with both dabigatran doses compared to warfarin (Larsen et al., 2013). 
Major bleeding was not significantly different between dabigatran and warfarin, but 
intracranial bleeding was markedly lower with both doses of dabigatran (Larsen et al.). 
Interestingly, myocardial infarction (MI) was significantly lower with dabigatran treated 
patients (both groups) compared to warfarin (Larsen et al. , 2013). This could be simply due 
to the fact that physicians could be choosing to avoid dabigatran in patients at higher risk of 
Mls (Larsen et al.). 
Following this early postmarket study, a further analysis of long-term outcomes was 
published by the investigators from RE-LY: the RELY -ABLE study (Connolly, Wallen tin, et 
al., 20 13). The patients in this study were the same ones assigned to dabigatran during the 
RE-LY trial, provided that they did not discontinue therapy after the study ended. Overall 
patients enrolled on RELY -ABLE were less likely to have had a major event during RE-LY, 
more likely to be male and have paroxysmal rather than permanent AF, and less likely to 
have a history of heart failure (Connolly, Wallentin, et al.). 
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Patients were followed for additional 28 months (median 2.3 years) and investigators 
concluded that the rates of major events were not inconsistent with those seen in RE-LY 
(Connolly, Wallentin, et al. , 2013). In the comparison of the 2 dabigatran doses in RELY-
ABLE, there was no significant difference in stroke or mortality, but there was a higher rate 
of major bleeding with the higher dabigatran dose (Connolly, Wallen tin, et al.). As the 
authors have acknowledged, this study has significant limitations, in that only one-half of the 
patients continued from RE-LY to RELY -ABLE, no event adjudication was done, and data 
analysis was not by the intention to treat (Connolly, Wallentin, et al., 2013). Furthermore, 
patients may have been at lower risk of events (Connolly, Wallentin, et al.). 
Controversies and clinical complications. Another concern in regards to dabigatran 
safety was raised during the food and drug administration (FDA) approval process. A 
numerical increase in the number of nonfatal Mls in the group receiving dabigatran was 
observed in the RE-LY study, and the agency requested a repeated data analysis, which 
revealed four previously unreported clinical Mls and 28 silent MI events (Hohnloser et al., 
2012). After those cases were included there was no longer a statistically significant 
differences in the rate of new Mls among the 3 groups, and all hazard ratios (HRs) were 
associated with wide confidence intervals (Hohnloser et al.). Nevertheless, a review of 7 
randomized controlled trials done by Uchino and Hernandez (cited in Cairns, 2012b) found 
that with dabigatran, the relative risk increase for MI or acute coronary syndrome (ACS) was 
33% and the relative risk reduction for death was 11 % compared with warfarin, enoxaparin, 
or placebo. However, the absolute risk increase (ARI) for MI or ACS was only 0.27%, and 
the ARR for death was only 0.05 % (Uchino & Hernandez, cited in Cairns , 2012). 
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In practical terms and according to the repeated data analysis gathered from RE-LY 
(Hohnloser et al., 2012) , you could estimate approximately 1 MI for every 77 people treated 
with dabigatran 150mg, versus one for every 95 people treated with warfarin, but as 
mentioned above, the Cis were wide and this number could be less or more than what we 
know now. Nevertheless, there was an overall net benefit with dabigatran 150mg compared 
with warfarin, even in patients with previous MI or CAD, and there is no evidence that 
dabigatran causes MI and the benefits of dabigatran for the prevention of stroke substantially 
outweigh the increase in MI (Hohnloser et al., 2012; Paikin et al., 2011) . 
Concerns have also been raised about the study design shortly after the publication of the 
results. One of the first organizations to bring the results into question was the Therapeutics 
Initiative (20 11) , who published a letter with a title "Can we rely on RE-LY?", stating that 
the comparison between warfarin and dabigatran was not blinded and thus all outcomes are 
subject to performance and ascertainment bias favoring dabigatran . The FDA committee was 
also concerned that the investigators filling out the report of events (called CRFs) for each 
hospitalization were unblinded, and hospitalization records were not reviewed for all 
hospitalizations (FDA, Center for Drug Evaluation and Research (COER) & Cardiovascular 
and Renal Drugs Advisory Committee (CRDAC), 2010) . This could have introduced bias 
into what was reported and what was not and consequently missed events . They have 
approved dabigatran for use in AF nevertheless . 
The investigators in the RE-LY trial defend their open trial design justifying that this 
way they were able to use the drugs in clinical practice the way physicians would normally 
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use them and reflect a "real world" comparison (Paikin et al., 2011) . They also defend that to 
diminish the risk for bias , a PROBE (Prospective, randomized, open-label, blinded-endpoint) 
design was utilized, with numerous strategies to minimize bias, including use of a double-
blind comparison of the two doses of dabigatran etexilate, the use of objective and well-
defined outcome events, screening for outcome events at each follow-up visit, and blinded 
adjudication of those events by two independent adjudicators (FDA, CDRER & CRDAC, 
2010; Paikin et al., 2011). 
Another critique is the significant and unequal drop out rates in both the dabigatran 
150mg and warfarin group (21 % and 16.6% respectively) without clarification about what 
was the course of therapy for these patients (DiNicolantonio , 20 12). If the dabigatran drop 
out patients were put on warfarin, the RE-LY data could have been 79% dabigatran plus 21 % 
warfarin versus 83.4% warfarin plus 16.6% antiplatelet therapy (which is known to be 
inferior than warfarin) (DiNicolantonio). This could have effectively skewed the results in 
favor of dabigatran. Finally, the negative outcomes of dabigatran need to be considered. For 
example, dabigatran increased MI by 0.4%, withdrawal due to serious adverse event by 1%, 
and withdrawal due to any adverse effect by 4.1% (Therapeutics Initiative, 2011). Patients 
taking dabigatran had more gastrointestinal bleeding, twice the likelihood of dyspepsia, and 
discontinuation therapy almost 50% more often in the first year of therapy (Cairns, 2012a). 
DiNicolantonio (20 12) also points out that 21 % of the patients in the RE-LY trial 
were taking a combination of warfarin and aspirin , despite conclusive evidence in the 
literature that this combination significantly increases major bleeding events. This could have 
translated into a 1-2% absolute risk increase in major bleeds per year compared with warfarin 
alone (DiNicolantonio). Furthermore, NSAIDS use was also greater in the warfarin group-
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combination that is also known for increased bleeding risk (Hauta-aho, Tirkkonen, Vahlberg, 
et al., cited in DiNicolantonio). If all the additional major bleeding episodes caused by the 
addition of aspirin and NSAIDS to warfarin were excluded from the statistics, warfarin, not 
dabigatran, would have caused fewer major bleeds, with a nonsignificant difference in deaths 
when compared to dabigatran 150mg (DiNicolantonio, 2012). 
Questions were also raised in regards to the inadequate time in therapeutic range 
(TTR) for warfarin obtained in some countries during the RE-LY trial. TTR was as low as 
54.3% in eastern Asia, and as high as 73% in North Europe (Van Spall et al., cited in 
DiNicolantonio, 2012), and there were infrequent INR measurements in patients both with 
adequate INR or inadequate INR (FDA, CDER & CRDAC, 2010). Therefore it is 
questionable if the "poor" outcome of warfarin in relation to dabigatran in RE-LY was 
simply due to poorly managed INR. Others argue that to have a stroke rate similar to that of 
the dabigatran (150 mg twice daily) group, patients randomized to warfarin in RE-LY would 
need to have a therapeutic INR 79% of the time, which is unlikely to be achieved in clinical 
trials or clinical practice (Gage, 2009). 
Another criticism is the higher rate of major bleeding observed with warfarin 
(3 .36% ), when historically, major bleeding rates have been reported varying from 0.86% to 
2.21 o/o in previous trials (Hughes et al., Lippi et al., Executive Steering Committee SPORTIF 
III investigators, & SPORTIF V investigators, cited in DiNicolantonio, 2012). The definition 
of major bleeding was broader in the RE-LY trial, but some argue that this alone cannot 
explain this increased bleeding risk with warfarin, and could have biased the results in favor 
of dabigatran (DiNicolantonio). 
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Furthermore, if you consider only the patients with a TTR ;:::65 .5% for the outcome of 
stroke or systemic embolism obtained in RE-LY, the results change, showing a non-
significant benefit with dabigatran 150mg vs warfarin (HR 0.69; 95% CI [0.44, 1.09]); and a 
borderline significant increase in overall mortality with dabigatran 150mg vs warfarin (HR of 
1.08; 95% CI, [0.74, 1.98]) and dabigatran 110mg (HR of 1.18, 95% CI [0.89,1.57]) 
(Wallentin, Yusuf, & Ezekowitz, cited in DiNicolantonio). Dabigatran 150mg significantly 
increased major bleeds compared to warfarin at TTR >72.6% (HR 1.16; 95% CI 
[0.88,1.54]), with event rates of 3.60 versus 3.11 (rate per 100 person-years) , respectively 
(Wallentin et al., 2010). However, both doses of dabigatran reduced intracranial bleeding in 
comparison to warfarin, irrespective of centres quality ofiNR control (Wallentin et al.). 
In summary, RE-LY is the only large RCT available for dabigatran use in patients 
with AF for stroke prevention, funded by the pharmaceutical company that will profit from 
its adoption in the market, and it was open-label. What this discussion has demonstrated is 
that there are significant questions about the design and results of this trial. Although the 
promise of fewer strokes with less adverse events such as intracranial bleeding is a good one, 
the evidence available is not clear and perfect. What RE-LY has shown is that dabigatran is 
an effective and relatively safe anticoagulant, but the claim that dabigatran 150mg is better 
than warfarin cannot be made until further research validate the initial results. When using 
this therapy the NP will need to consider several factors in order to optimize stroke risk 
management in patients with non-valvular AF, such as: the demographics in which the 
patient fits ; the risk of bleeding; the time in TTR (if previously using warfarin); potential for 
adequate warfarin TTR management; concomitant use of other blood thinners (ie. aspirin , 
NSAIDS, clopidrogel) and other medications; and previous medical history (ie. Coronary 
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artery disease and gastric ulcer). Providing a comprehensive assessment of these factors will 
enable the NP to provide optimal management of AF. 
Rivaroxaban. Rivaroxaban has been approved in Canada for the prevention of stroke 
and systemic thromboembolism in AF and atrial flutter and is another agent that the NP may 
select for managing this patient population. This section will provide a brief overview of the 
relevant pharmacology, as well as present the evidence from the rna jor clinical trials. 
Pharmacology. Rivaroxaban is an oral direct factor Xa inhibitor that exhibits 
predictable, dose-proportional pharmacokinetics, with a high oral bioavailability and a rapid 
onset of action (Kubitza, Becka, & Wensing et al., cited in The Executive Steering 
Committee, 2010).) It has a mean terminal half-life after multiple oral doses between 7 and 
11 hours (Ahrens & Bode, 2012). Factor Xa is an attractive biological target because of its 
amplifying effect (Littrell & Flaker, 20 12). Approximately one third of rivaroxaban is 
eliminated unchanged by the kidneys. The remaining approximately two thirds of the drug is 
metabolized by the liver, after which half of the metabolized fraction is excreted in urine and 
the other half excreted in feces (Weinz, Schwarz, & Kubitza et al. , cited in The Executive 
Steering Committee, 2010). Therefore, patients with moderate impaired renal function 
(creatinine clearance: 30-49ml/min) should receive reduced dosages of rivaroxaban (Ahrens 
& Bode, 2012). Because rivaroxaban has a low propensity for drug-drug interactions, and 
there are no reported food-drug interactions , or dietary restrictions necessary, the 
manufacturer states that monitoring of anticoagulation intensity is not required (The 
Executive Steering Committee, 201 0). 
To date , there are two large phase III RCTs available for Rivaroxaban in patients with 
AF: the ROCKET (The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared 
-with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation) and the J-ROCKET (J standing for Japanese). These will be presented in the 
following sections. 
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Clinical trials. The ROCKET trial was a randomized, double-blind, double-dummy , 
event-driven trial against warfarin to establish noniferiority of rivaroxaban in patients with 
non-valvular AF and a history of stroke or at least 2 additional independent risk factors for 
future stroke (The Executive Steering Committee, 201 0). Two doses of rivaroxaban were 
tested against warfarin: 20 mg daily or 15 mg daily in patients with a creatinine clearance of 
30 to 49 ml per minute. The study included 14,264 patients with moderate to high risk for 
future thromboembolic events as a result of previous stroke, TIA, or systemic embolism; and 
with 2 or more of the following risk factors (The Executive Steering Committee, 2010): 
clinical heart failure and/or left ventricular ejection fraction :s;35 %, hypertension , age ~75 
years, or diabetes mellitus . 
Of all the novel oral anticoagulants RCTs, ROCKET was the one with the highest 
mean CHADS2 score (3.5), and only 10% of the patients had not had a previous ischemic 
stroke, TIA, or systemic embolism and had no more than two risk factors (Patel et al., 2012). 
The median follow up was 1.9 years. The primary efficacy end point was the composite of 
stroke (ischemic or hemorrhagic) and systemic thromboembolism (STE) (Petel et al., 2011). 
Secondary efficacy end points included a composite of stroke, STE, or death from 
cardiovascular causes; a composite of stroke, STE, death from cardiovascular causes, or MI; 
and individual components of the composite end points (Petel et al.). The principal safety end 
point was a composite of major and nonmajor clinically relevant bleeding events (Petel et 
al.). 
34 
The ROCKET trial has one major advantage over the RE-LY trial in that it was 
double-blinded . Patients were taking either warfarin or rivaroxaban , without knowledge of 
which one was a placebo, and monitoring INRs regularly (with sham results provided for the 
patients on rivaroxabam). This strategy reduces bias significantly and adds strength to the 
data collected during the trial. 
The J-ROCKET trial had essentially the same design as the global ROCKET, but 
with a smaller dose (15mg once a day) due to decreased plasma levels observed with 
Japanese patients and lower anticoagulation targets currently used by Japanese physicians 
(INR target of 1.6-2.6) (Hori et al., 2012). In a multicultural society as Canada, the results of 
such trials are relevant for the care of Japanese patients . Therefore they are included in this 
analysis. 
The J-ROCKET included 1,180 Japanese patients with moderate to high risk for 
thromboembolic events and a history of prior ischemic stroke, TIA, or non-central nervous 
system (CNS) systemic embolism or two or more of the following risk factors: congestive 
heart failure and/or left ventricular ejection fraction :S:35%, hypertension, age '?::.75 years, or 
diabetes mellitus. The mean CHADS2 score was 3.25 and the mean age of the participants 
was 71.1 . Patients with baseline moderate renal impairment (CrCl 30-49 ml/min) received a 
reduced 10 mg o.d. rivaroxaban regimen (22.1 %) (Hori et al. , 2012). Primary efficacy end 
point was the composite of adjudicated all-cause stroke (ischemic or hemorrhagic) and non-
CNS systemic embolism (Hori et al.). Secondary efficacy endpoints included a composite of 
stroke, systemic embolism, and vascular death and a composite of stroke, systemic 
embolism, vascular death , and MI (Hori et al.). Due to the small sample, this study was not 
powered to test efficacy hypotheses. 
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Findings. In ROCKET, rivaroxaban was non-inferior to warfarin in the prevention of 
subsequent stroke or systemic embolism (HR 0.79; CI [0.65, 0.95]) (Petel et al. , 2011) , with 
an ARR of 0.3% based on intention-to-treat analysis. Principal efficacy outcome rates 
(strokes plus STEs) were 2.4% per year with warfarin and 2.1 % per year with rivaroxaban 
(RR 0.88, 95 % CI [0.75, 1.03]) based on intention-to-treat analysis . Similar to dabigatran , 
such a low ARR might translate to 1 or 2 less strokes, depending on the number of patients 
treated and time. There were no significant differences in rates of major and clinically 
relevant non-major bleeding between the two study groups , with major bleeding rates of 
3.4% per year with the warfarin group and 3.6% with rivaroxaban (RR 1.04), although 
intracranial and fatal bleeding occurred less frequently in the rivaroxaban group (Petel et al. , 
2011) . Bleeding that proved fatal or involved a critical anatomical site occurred less 
frequently in the rivaroxaban group, mainly because of lower rates of hemorrhagic stroke and 
other intracranial bleeding (Patel et. al) . It is also interesting to note that the rate of Mis was 
lower in the rivaroxabam group- 0.9% versus 1.1% in the warfarin group- and the number 
of deaths was also lower: 1.9% versus 2.2% respectively. 
In a subset analysis of patients with a previous stroke or TIA, there was no evidence 
that the relative efficacy and safety of rivaroxaban compared with warfarin was different 
between patients who had a previous stroke or TIA and those who had no previous stroke or 
TIA (Hankey et al., 2012) . Nevertheless, investigators point out that errors in the assessment 
of previous stroke or TIA might have introduced some misclassification bias , which might 
have led to underestimation or overestimation of the HRs in these subgroups (Hankey et al.). 
Unlike dabigatran , there is no subgroup analysis of patients who underwent cardioversion 
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while on rivaroxaban and the utility of rivaroxaban for preventing post-cardioversion stroke 
and systemic embolism is unknown (Bayer, 2013). 
In J-ROCKET the primary efficacy rates in the per-protocol population were 2.38% 
per year in patients receiving rivaroxaban , versus 2.91 % per year in patients receiving 
warfarin (HR 0.82; 95 % CI [0.46, 1.45]) (Hori et al., 2012). These results are very similar to 
the ROCKET rates on the intention-to-treat analyses (2.1 % vs 2.4% for rivaroxabam versus 
warfarin) (Hori et al.). 
Major bleeding rates were lower with rivaroxaban , at 3% per year versus 3.59% per 
year with warfarin (HR 0 .85 ; 95 % CI [0.50, 1.43]) (Hori et al., 2012). But the composite of 
adjudicated major bleeding and non-major clinically relevant bleeding events, was higher in 
the rivaroxaban group (18.04% versus 16.42% per year respectively; HR 1.11; 95% CI [0 .87, 
1.42]) (Hori et al.) . Over the entire treatment period, 65 % of the INR values of warfarin-
treated patients were within the pre-specified, age-dependent target range (Hori et al., 2013) 
Overall, the data with J-ROCKET is very much comparable to the data obtained with 
ROCKET, despite the decreased dosages of rivaroxaban and warfarin , suggesting that 
anticoagulation in this population does need to be pursued with lower INR targets and lower 
rivaroxaban dosing. Due to the similarity of the results , the remaining of this analysis will 
focus on data from the ROCKET trial. 
Translating the data. In practical terms, imagine a population consisting of 1,000 
patients with AF and similar demographics to the study population. According to the data 
collected during ROCKET, we could expect 17 patients in the rivaroxabam group to have a 
stroke (ischemic or hemorrhagic) in the course of one year, versus 22 in the warfarin group. 
That is , 5 less strokes in the group treated with rivaroxaban. Furthermore, we would expect 
37 
36 (3.6%) patients from our hypothetical population to develop a major bleeding event while 
on rivaroxabam, and 34 patients to develop the same complication while on warfarin (3.4%). 
That is an ARR of only 0.2% in favor of warfarin. Of these bleeding events, intracranial 
hemorrhage rates would be similar with 0.8% in the rivaroxaban arm versus 1.2% in the 
warfarin group. Appendix G shows the projected number of events for a hypothetical group 
being treated with rivaroxaban 20mg once a day versus dose adjusted warfarin, dabigatran 
150mg, or apixaban for one year. These numbers show rivaroxaban as a viable alternative to 
warfarin, and safer than dabigatran in terms of MI prevention. Nevertheless, the difference in 
outcomes is still too small to prove superiority over warfarin. 
It is also important to note that the results of rivaroxaban did not differ across 
quartiles of the duration of time that INR values were within the therapeutic range according 
to study center (p = 0.74 for interaction) (Bruins Slot & Berge, 2013; Patel, et al., 2011). 
Nevertheless , average warfarin TTR was 55%, which is quite low, and therefore warfarin 
performance might have been poorer than expected, skewing results in favor of rivaroxaban. 
This is especially plausible to consider when we look at an ARR of only 0.3%, even with 
such a large study group. 
Similarly to what happened with dabigatran, bleeding rates in warfarin were high 
compared to historical trials . Despite it's poor performance, warfarin major bleeding rates 
were slightly lower than rivaroxabam (3.4% versus 3.6% respectively). To put that in 
perspective, historical major bleeding rates of warfarin range from 0.86% to 2.21 % (Hughes 
et al., Lippi et al., Executive Steering Committee SPOTIF III investigators, & SPORTIF V 
investigators , cited in DiNicolantonio, 2012) . The investigators justify warfarin ' s poor 
performance due to the fact that earlier trials of warfarin included fewer high-risk patients, 
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and no previous studies addressed patient populations with overall levels of coexisting 
illnesses and geographic diversity that were similar to those of the patients in the ROCKET 
study (Patel eta! , 2011) . Investigators also point out that patients with previous stroke or TIA 
who were assigned to warfarin had an INR in the therapeutic range just over half the time, on 
average, suggesting that high-risk patients are often managed suboptimally in clinical 
practice as well as in the context of a clinical trial, which suggests that there is a widespread 
deficiency in care (Pengo, Pegoraro, Cucchini , & Iliceto cited in Hankey et al. , 2012) . 
Also relevant is the high percentage of patients taking warfarin and aspirin 
concomitantly during the ROCKET trial (36.2% for the warfarin group versus 36.9% in the 
rivaroxaban group) . As previously discussed, bleeding risk is significantly increased when 
warfarin taken with aspirin. Concomitant aspirin use (almost exclusively at a dose of 100 mg 
or less) with either rivaroxaban or warfarin during the ROCKET trial was identified as an 
independent risk factor for major bleeding (Bayer, 2012). Such a high rate of aspirin use 
could have potentially favored bleeding rates for rivaroxaban , but major bleeding rates were 
still lower for warfarin. 
In summary, Rivaroxaban has been shown to offer similar efficacy as warfarin with 
the advantage of convenience of use. Nevertheless it is unknown if this would still hold true 
if warfarin was being used with a higher TTR and without concomitant aspirin. The NP in 
clinical practice knows that maintaining adequate INR and compliance are the very issues 
that brought the necessity of alternative anticoagulation therapies to the market, since this is 
not always achievable with every patient. Therefore , for NPs and patients these results are 
encouraging in the sense that they show an effective therapy , but they cannot replace the 
successes of warfarin therapy neither prove superiority. 
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Controversies and clinical complications. In terms of design, the ROCKET trial has 
faced much less criticism than the RE-LY trial, probably because of the double-blinded 
design, but has been criticized for performing its efficacy and safety analyses on the basis of 
per protocol rather than the intention-to-treat population (although the as-treated population 
excluded only 28 of 14,264 patients) (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012). 
Furthermore, some of the criticisms, such as the high levels of aspirin use and low TTRs are 
applicable to both studies as discussed above. 
Concerns regarding a potential increased risk of events after discontinuation led the 
United States FDA to require a boxed warning on the package insert stating "discontinuing 
rivaroxaban places patients at increased risk of thrombotic events", and "an increased risk of 
stroke was observed following rivaroxaban discontinuation in clinical trials in atrial 
fibrillation patients" (FDA cited in Patel et al., 2013). In a post-hoc analysis the investigators 
found no significant differences between rivaroxaban and warfarin after short interruptions or 
early permanent discontinuation , but there were significantly more strokes and non-CNS 
embolism events in patients who had received rivaroxaban compared with those who had 
received warfarin after the end of the study and subsequent mandatory withdrawal of the 
blinded study drug (Patel et al., 2013). Further studies are necessary to understand how to 
best transition patients from rivaroxaban to warfarin. 
Apixaban. Apixaban was approved for stroke prevention in patients with AF in 
Canada in 2012 . Following is an overview of its pharmacological action and a critical review 
of the key trials and research studies. 
Pharmacology. Apixaban is an orally active selective inhibitor of coagulation factor 
Xa, with a half-life around 12 hours, >50% bioavailability and plasma levels are achieved in 
40 
3 hours (Littrell & Flaker, 2012; Lopes et al., 2010). It also inhibits clot bound factor Xa in 
vitro (Jiang, cited in Nutescu, 2012). Interestingly, it has a 3.5-fold less peak-to-through 
fluctuation than rivaroxaban, which could theoretically improve its benefit-risk profile 
(Littrell &Flaker, 2012). Similarly to rivaroxaban, there is no need for regular monitoring and 
dose titration. 
Different than dabigatran and rivaroxaban, apixaban has a predominantly non-renal 
(75 %) clearance and is metabolized primarily by the liver via the CYP3A4 and other 
mechanisms (Littrell & Flaker, 2012), which are attractive properties for the management of 
patients with kidney impairment. Following, the two RCTs available for apixaban will be 
discussed. 
Clinical trials. To date there are 2 large phase III RCTs for apixaban in patients with 
AF. A VERROES (apixaban versus acetylsalicylic acid to prevent stroke in AF patients who 
have failed or are unsuitable for vitamin K antagonist treatment) compared apixaban to 
aspirin for the endpoint of stroke and systemic thromboembolism , while ARISTOTLES 
(apixaban for reduction in stroke and other thromboembolic event in AF) compared apixaban 
to warfarin for the same outcome. Although A VERROES did not involve warfarin, it is the 
only RCT comparing novel anticoagulant to antiplatelets in AF, and therefore the results are 
relevant to this literature review. 
A VERROES was a large double-blind , double-dummy superiority trial of apixaban 5 
mg twice daily (2.5 mg twice daily in selected patients) compared with aspirin 81 to 324 mg 
once daily in 5599 patients with AF and at least 1 risk factor for stroke who have failed or are 
unsuitable for VKA therapy, who were followed-up for 1.1 years (Eikelboom, O'Donnell, et 
al., 2010). The primary efficacy outcome was stroke (ischemic or hemorrhagic) or systemic 
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embolism and the primary safety outcome was major bleeding. Aspirin dose was decided at 
the discretion of the local investigator, with no specific parameters, from 81 to 325mg daily . 
The standard 5mg BID dose of apixaban was reduced to 2.5mg BID in patients with age ~80 
years, or body weight ~60 kg, or serum creatinine ~1 .5 mg/dL or 133 11mol/L (Eikelboom et 
al., 2010). 
Patients were not receiving vitamin K antagonist therapy either because it had already 
been demonstrated unsuitable for them or because it was expected to be unsuitable for 
reasons such as poor INR control, unwanted drug interactions, or unwillingness to adhere to 
monitoring and INR control (Eikelboom et al., 2010). Patients enrolled were 50 years or 
older, with AF and at least one of the following risk factors: prior stroke or TIA; age ~75 
years old; arterial hypertension on treatment; diabetes mellitus; heart failure (New York 
Heart Association class ~2) or left ventricular ejection fraction ~35%; or peripheral arterial 
disease. 
ARISTOTLE was a phase III randomized, double-blind trial, comparing apixaban 
(5mg BID) with warfarin (target INR, 2.0 to 3.0) in 18,201 patients with AF and at least one 
additional risk factor for stroke, such as: age of at least 75 years; previous stroke, TIA, or 
systemic embolism; symptomatic heart failure within the previous 3 months or left 
ventricular ejection fraction of no more than 40%; diabetes mellitus; or hypertension 
requiring pharmacologic treatment (Granger et al., 2011). The primary efficacy outcome was 
stroke (ischemic or hemonhagic) or systemic embolism and the primary safety outcome was 
major bleeding. Death from any cause and MI were secondary efficacy outcomes. The 
secondary safety outcome was a composite of major bleeding and clinically relevant 
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nonmajor bleeding, other adverse events , and liver-function abnormalities (Granger et al. , 
2011). 
The mean CHADS2 score was 2.1 (same as dabigatran but lower than rivaroxaban), 
the mean age was 70 years old and the median follow up was 1.8 years (Granger et al., 2011). 
Only patients with AF or flutter at enrollment or two or more episodes of AF or flutter, as 
documented by electrocardiography, at least 2 weeks apart in the 12 months before 
enrollment were included (Granger et al., 2011). 
Findings. In AVERROES, apixaban was much more effective than aspirin for the 
prevention of stroke, with a bleeding risk similar to that of aspirin (Connolly et al., 2011). 
The primary outcome occurred at a rate of 3.7% per year in the aspirin group versus 1.6% in 
the apixaban group (HR with apixaban 0.37; 95% CI [0.32, 0.62]) (Connolly et al., 2011). 
Interestingly, intracranial bleeding occurred at the same rate for both drugs (0.4% per year), 
and major bleeding rates were also comparable at 0.9% in the aspirin group and 1.4% in the 
apixaban group (HR 1.54; 95 % CI [0.96, 2.45];p = 0.07) (Connolly et al., 2011). This data is 
especially relevant when one considers that adjusted dose warfarin doubles the risk for 
intracranial hemorrhage compared with aspirin (Hart, Pearce, & Aguilar, 2007). 
Also noticeable is the fact that significantly fewer patients in the apixaban group had 
a serious adverse event (22% versus 27%,p < 0.001) (Connolly et al., 2011). As the 
investigators explain it, on the basis of the intention-to-treat analysis, treating 1000 patients 
for I year with apixaban rather than aspirin would prevent 21 strokes or systemic emboli, 9 
deaths, and 33 hospitalizations for cardiovascular causes, at the cost of 2 major bleeding 
events (Connolly et al., 2011). The study was stopped early upon the recommendation of the 
trial's independent Data Monitoring Committee which found that a pre-defined interim 
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analysis revealed clear evidence of apixaban providing a clinically important reduction in 
stroke and systemic embolism and acceptable safety profile (Pfizer Canada & Bristol-Myers 
Squibb Canada, 2012). 
In ARRISTOTLE, apixaban significantly reduced the risk of stroke or systemic 
embolism by 21 %, major bleeding by 31%, and death by 11 % in comparison to warfarin 
(Granger et al., 2011). Stroke rates were 1.27% per year with apixaban, compared with 
1.60% per year with warfarin (HR in the apixaban group, 0.79; 95 % CI, 0.66 to 0.95; 
p<0.001 for noninferiority and p=0.01 for superiority) (Granger et al., 2011). 
In terms of bleeding risk, apixaban also compared well with warfarin. Major bleeding 
rates were significantly lower with the apixaban group (2.13% versus 3.09% per year with 
warfarin) (HR, 0.69; 95% CI [0.60, 0.80]; p < 0.001), and intracranial bleeding occurred in 
0.33 % of the patients on apixaban, versus 0.8% of the patients on warfarin (HR, 0.42; 95% 
CI, [0.30, 0.58]; p < 0.001) (Granger et al., 2011). Apixaban prevented a hemorrhagic stroke 
in 4 patients per 1000 treated and an ischemic or unknown type of stroke in 2 patients per 
1000 (Granger et al.) The rate of myocardial infarction was lower in the apixaban group than 
in the warfarin group, but the difference was not significant (Granger et al.). 
Patients with previous stroke or TIA had a two to three times higher risk of stroke or 
systemic embolism, major bleeding, intracranial hemorrhage (ICH), and mortality than those 
without previous stroke or TIA (Easton, 2012). A subgroup analysis revealed similar results 
to the main group and showed that patients with and without previous stroke or TIA treated 
with apixaban seemed to have fewer strokes, major bleeds (including ICH), and lower 
mortality than patients treated with warfarin, although these benefits were not all statistically 
significant (Easton). Of the 3.2% (49.6% from the apixaban group and 50.4% from the 
warfarin group) of the patients that underwent cardioversion during the ARISTOTLE trial, 
none developed a stroke or systemic embolism during the 90 days following the procedure 
(Pfizer Canada & Bristol-Myers Squibb Canada, 2012). 
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Translating the data. For a similar analysis described previously with dabigatran and 
rivaroxaban, imagine a population of 1,000 patients with the same demographics as the trial 
population. ARISTOTLE data shows that we could expect 12 strokes or systemic embolism 
cases in the group treated with apixaban versus 16 in the warfarin group. That is 4 less 
strokes in the group treated with apixaban versus the group treated with warfarin. In terms of 
bleeding risk, we could expect 40 patients in the apixaban group to develop a major bleed or 
a nonmajor clinically significant bleed, versus 60 patients among those treated with warfarin. 
Of those , 3 would be intracranial bleeds in the apixaban group, versus 8 in the warfarin 
group. That amounts to an almost 2% ARR (1.94%) (See Appendix G). 
Although the number of strokes and systemic embolisms is very low, the ARR of 
apixaban in relation to outcomes with warfarin is similar to other novel oral anticoagulants 
(0.33%). This might be due to better TTR, a younger population with lower CHADS2 scores, 
or most likely, the combination of the two. Nevertheless, apixaban was deemed superior to 
warfarin in the ARISTOTLE trial . The biggest advantage of apixaban might lie in the 
significant reduction in major bleeding and intracranial bleeding in comparison to warfarin, 
and similar bleeding rates in comparison to aspirin. For example, while the ARR of major 
bleeding with rivaroxaban in comparison to warfarin was only 0.2%, with apixaban it was 
almost 1% (0.96% ). 
The median TTR in ARISTOTLE was 66%, varying from 49% to 78% across clinical 
centers (Gallego, Vilchez, & Lane, 2013). In a post hoc analysis of the implications of TTR, 
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investigators concluded that the reduction in stroke and systemic embolism with apixaban 
compared with warfarin remained the same regardless of the quartile of predicted center TTR 
and that the superior efficacy and safety of apixaban over warfarin, even compared with 
optimal anticoagulation with warfarin (TTR ~70%), suggesting that the benefits of apixaban 
are not simply a result of sub optimal control in the trials (Gallego, Vilchez, & Lane; 
Wallentin et al. 2013). 
The same criticism of abnormally elevated bleeding rates on the warfarin arm in 
comparison to historical trials applies to ARISTOTLE, even though according to Gallego, 
Vilchez, & Lane (2013) the INR variability was driven primarily by sub therapeutic INRs, 
which would predispose the warfarin group to stroke, not bleeding. Nevertheless, bleeding 
rates for warfarin were lower in the ARISTOTLE trial than in ROCKET and RE-LY (3.09% 
versus 3.4% and 3.6% respectively). The younger population and the lower CHADS2 scores 
in ARISTOTLE in comparison to the ROCKET trial could probably explain this . 
Interestingly, the exclusion criteria in the ARISTOTLE trial was less stringent as compared 
with the other trials, making it more likely to represent the population treated in clinical 
settings with a better relationship between efficacy and effectiveness (Pengo et al., 2012). 
As for the percentage of aspirin use (31% and 33% respectively for apixaban and 
warfarin), it was lower than ROCKET, but still problematic for interaction with warfarin and 
elevation of warfarin bleeding rates. Concomitant aspirin use with either apixaban or 
warfarin increased the risk of major bleeding 1.5 to 2 times when compared with those 
patients not treated with concomitant aspirin (Pfizer Canada & Bristol-Myers Squibb Canada, 
2012). 
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In summary, off all the novel oral anticoagulants discussed, apixaban is the only one 
that has shown superiority over warfarin in both efficacy and safety. The NP needs to 
carefully consider these results and contrast them with the limitations that still exist, as well 
as other factor that will affect decision-making, such as cost and patient's preferences . The 
advantages do not render apixaban a perfect solution for stroke prevention in patients with 
AF. Significant limitations still apply to both the trial results and clinical use. 
Controversies and clinical complications. The results in AVERROES , as promising 
as they were, were not free of criticism. While there was no appreciable increase in major 
hemorrhage seen with apixaban over aspirin, the confidence interval around hazard ratio 
(particularly for the on-treatment analysis) was relatively wide (Hart, 2011 ). Drug 
interactions with apixaban, particularly with those metabolized through the CYP450 system, 
have not been fully elucidated and optimal dosing of apixaban may require further 
refinement, particularly for patients with renal or liver disease (Hart, 2011). 
In summary, apixaban offers excellent results for safety and efficacy in stroke 
prevention in AF, with the added advantage of a safer renal profile. Nevertheless, there are 
still many limitations , such as lack of a reversal agent, that need to be considered and 
clarified by further research. Some of these limitations will be further discussed in the 
clinical decision making section of this analysis. The NP will need to carefully consider the 
risk of bleeding of each patient, consider that there is no antidote, and always keep in mind 
the group of patients that were excluded from the trial (including patients with severe renal 
impairment). 
Indirect comparisons and meta-analysis. A total of 6 meta-analysis and indirect 
comparisons were found during the literature search comparing dabigatran , rivaroxaban, 
apixaban and warfarin. Of those , four focused on the RCTs previously discussed (RE-LY, 
ROCKET AND ARISTOTLE) and 2 included other phase II studies only with the 
medications dosages included in phase III trials. 
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Adjusted indirect comparisons usually but not always agree with the results of head to 
head randomized trials (Song, Altman, Gleeny, & Deeks , 2003). When there is no or 
insufficient direct evidence from randomized trials, the adjusted indirect comparison may 
provide useful or supplementary information on the relative efficacy of competing 
interventions (Song et al. 2003). It is important to highlight that it is not possible to adjust for 
population differences between trials when doing an indirect comparison and that the 
conclusions rely on assumptions of study homogeneity and similarity (Skjoth, Larsen, & 
Rasmussen, 2012). 
Considering that all 3 drugs (dabigatran, rivaroxaban and apixaban) were tested 
against one common variable (warfarin titrated to INR 2-3) , it is possible to perform adjusted 
indirect comparisons . The main differences to be taken into consideration are mean TTR and 
CHADS2 scores, which varied in different studies and have some impact on the results, since 
populations with low TTRs are more prone to develop either stroke or bleeding, and patients 
with higher CHADS2 are more prone to develop complications, strokes and bleeding 
episodes. TTR was lowest on the ROCKET trial (58%), which was also the study with the 
highest mean CHADS2 score (3 .5) and median age of patients enrolled (73 years old) . RE-
LY and ARISTOTLE in turn had a TTR of 64% and 66% respectively; both had a mean 
CHADS2 score of 2.1, and similar median ages (71 and 70 years old respectively). 
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Findings. New oral anticoagulants were found to be similar and at least non-inferior 
to warfarin for the composite end point of stroke (including hemorrhagic stroke) and 
systemic embolism (Assiri , Al-Majzoub , Kanaan, Donovan , & Silva, 2013 ; Miller et al. , 
2012). When data were pooled across RCTs , patients randomized to the new oral 
anticoagulants had a 22% RR reduction for the composite end point of stroke and systemic 
embolism (Miller et al., 2012) . While RRs sound impressive , the ARRs do not sound as 
impressive. One large meta-analysis, including drugs in phase II trials that have not been 
included in this discussion , found the ARR with new oral anticoagulants to be 0.73% 
(Dentali, Riva, Crowther, Turpie, Lip, & Ageno, 2012). Another meta-analysis including 
only the phase III RCTs, showed an even smaller difference and concluded that novel oral 
anticoagulants were comparable to warfarin (OR 0.92; 95 % CI [0.83, 1.02],p = 0.1) (Testa et 
al. , 2012). Nevertheless , novel oral anticoagulants showed large superiority in terms of 
hemorrhagic strokes (OR 0.43 ; 95% CI [0.34, 0.55],p < 0.001) with a number needed to treat 
(NNT) to save on hemorrhagic stroke of 153 (Testa et al.). 
When compared against each other, none of the new oral anticoagulants was 
significantly superior to the others for the prevention of stroke and systemic emboli (Testa, et 
al. , 2012). All (except for one) confidence intervals of the derived ORs are between 0.65 and 
1.62 withp values above 0.05 (Mantha & Ansell, 2012). This suggests that a difference in 
primary outcome rates among novel oral anticoagulants might not actually exist, since the 
OR could be 1, or might be just due to chance (due to the high p values). That is, they are all 
comparable to each other, except for rivaroxaban versus dabigatran which had an OR of 1.35 
with a 95% CI of [1.02 , 1.78] and ap = 0.04, suggesting more events to patients exposed to 
rivaroxaban, but this might be due to the heterogeneity of the two populations being 
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compared as previously discussed . Interestingly only warfarin and apixaban are more 
protective than the combination of aspirin and clopidogrel for ischemic stroke (Assiri et al. , 
2013). 
In terms of major bleeding, only apixaban and dabigatran 110 were found to offer 
some advantage over the other oral anticoagulants (including warfarin). For dabigatran 
110mg, the HR against warfarin was 0.8 (95% CI [0.70 , 0.93]) , and for apixaban it was 0.69 
(95% CI [0 .60, 0.80]) (Mantha & Ansel , 2012). This means 20% less episodes of major 
bleeding with dabigatran 110mg, and 31 % less with apixaban than warfarin. When grouped 
together for analysis against warfarin, one meta-analysis found new oral anticoagulants were 
associated with a significant reduction in the rate of major bleeding events (RR 0.86; 95 % CI 
[0 .80, 0.93] ; NNT 157) , but the heterogeneity of that analysis was moderately high (i= 57%) 
(Dentali et al. 2012) . 
When compared to each other, one meta-analysis found that apixaban resulted in 12 
fewer gastrointestinal bleeds than dabigatran per 1000 patients treated, and 11 fewer than 
rivaroxaban (Baker & Phung, 2012) . Dabigatran 150mg was associated with a further 
reduced risk of hemorrhagic stroke compared to rivaroxaban , and apixaban showed reduced 
risk of extracranial major bleeding compared to dabigatran 150mg. Overall , use of new oral 
anticoagulants was associated with a significant reduction in the risk of intracranial bleeding 
events (RR 0.46; 95 % CI [0.39, 0.56]; t=34%; ARR 0 .71 %; NNT=141) (Dentali et al., 
2012). 
Opinions vary around MI risk . Two meta-analysis concluded that risk for MI was 
similar between new oral anticoagulants and warfarin (RR 0 .99; 95 % CI [0.85, 1.15]) 
(Dentali et al., 2012; Miller et al., 2012), but the heterogeneity was moderately high 
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(12=55%). One of them did a subgroup analysis assessing each novel drug, and found no 
statistically significant difference between the new oral anticoagulants and warfarin (Dentali 
et al.). Another adjusted indirect comparison concluded that the risk of MI was higher with 
both doses of dabigatran compared with other new oral anticoagulants (Testa et al., 2012). 
The other meta-analysis did not perform any comparison for this outcome. 
Newer anticoagulants and warfarin were similar regarding all-cause mortality (Assiri 
et al., 2013). One meta-analysis found that only apixaban had a clear survival benefit when 
compared to warfarin, with a HR of all-cause mortality of 0.89 (95% CI [0.80, 0.99]) 
(Mantha & Ansell, 20 12), but the upper limit of the CI is very close to 1. The indirect 
comparison for all-cause mortality did not suggest superiority of any new agent versus 
another (Mantha & Ansell). 
In summary warfarin and the novel oral anticoagulants were found to offer similar 
protection against stroke and have similar outcomes in terms of major bleeding, all-cause 
mortality and intracranial hemorrhage (Assiri et al. , 2013). Dabigatran, rivaroxaban and 
apixaban showed lower rates of intracranial bleeding than warfarin. There were fewer 
instances of non-major bleeding with apixaban than with warfarin and no difference in terms 
of major hemorrhage (Assiri et al.). Overall there was no advantage of the new oral 
anticoagulants as a group compared with warfarin in terms of mortality (Assiri et al.), but 
apixaban had a survival benefit compared to warfarin . Apixaban and dabigatran 150mg 
further demonstrated superiority to warfarin for the composite end point (Miller et al., 2012). 
The review of the clinical studies related to the novel anticoagulation agents 
demonstrates the complexity that underpins the clinical decision-making process for patients 
with non-valvular AF. These are major consideration for the NP when managing these 
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patients. Despite the excellent results identified in this review, some of the limitations both in 
the design of the RCTs, as well as inherent to the drugs themselves, exist and warrant further 
explanation. Of special relevance are: the lack of antidote; the inability to monitor 
anticoagulation levels; the lack of data about treatment in patients with renal and/or hepatic 
impairment; issues related to cost and adherence, safety profile, age and drug interactions . 
These will now be presented. 
Clinical Decision-Making 
This section synthesizes the data obtained from the clinical trials and discusses 
specific points that the NP will need to consider in the clinical decision-making process. 
First, it is important to highlight that in order to make and appropriate recommendation for 
oral anticoagulation in AF, the NP will need to involve the patient during the decision-
making process, considering his unique history and social-economic context. In a shared 
decision-making model, differently from the traditional paternalistic approach, the NP must 
inform the patient of all information that is relevant to making a treatment decision and in 
turn, the patient needs to provide information about his values, preferences, life- style, beliefs 
and knowledge about his illness and its treatment (Charles, Gafni, & Whelan, 1999). 
Patients are not so much interested in average outcomes for aggregate groups of 
patients as they are in knowing what this information means for themselves specifically 
(Charles et al.) . The patient should be fully informed about the pros and cons of the different 
treatment options, whether it is anticoagulation , rate control drugs, antiarrhythmic drugs, or 
interventional therapy (ESC, 2010). Pros and cons of warfarin and the new oral 
anticoagulants that should be discussed with each patient are exemplified in Appendix F. For 
example, for some patients the lack of an antidote for the new oral anticoagulants might be of 
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significant concern, and that should be further explored before making any decision. A quick 
internet search shows lawyers already recruiting patients treated with new oral anticoagulants 
for class law suits due to the inability of reversal of anticoagulation during a major bleeding 
episode. Full disclosure of such risks is not only necessary for patients, but it is also their 
right, after all the people whose preferences count are the patients, because they are the ones 
who will have to live (or die) with the outcomes (Eddy, cited in Charles et al. , 1999). 
As part of this review, a quantitative examination of the clinical trial data was 
undertaken, in addition to a more qualitative approach to examine contextual and patient care 
factors relevant to the management of patients with non-valvular AF. Following the appraisal 
of the research evidence, the following categories were identified as important themes that 
the NP should consider and discuss with each patient in order to tailor anticoagulation 
therapy to the needs of each individual: 1) risk, 2) demographics, 3) cost, 4) adherence, 5) 
safety and side-effect profile, 6) drug-drug and food interactions, 7) anticoagulation reversal, 
8) renal impairment, 9) age , 10) coronary artery disease , and 11) other limitations. These will 
now be discussed. 
Risk. The first discussion the NP should have with the patient is: do we need to start 
anticoagulation or not? That decision should be made with the patient and the NP would need 
to carefully assess the risk and the clinical profile of each patient, and then contrast it with 
the profile of each therapeutic agent. When weighing stroke risk against bleeding risk, the NP 
should keep in mind that stroke risk is generally greater than bleeding risk, and usually the 
stroke reduction observed with anticoagulation is larger than the associated increase in 
bleeding (ESC, 2012) . Both the Canadian Cardiovascular Society (CCS) and the ESC 
recommend patients with AF who have stroke risk factor(s) ~1 to receive oral anticoagulants 
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for effective stroke prevention therapy. Patients with a CHADS2 ~ 1 have a stroke-risk well 
over 2% per year and require oral anticoagulants (Skanes et al., 2012) . 
Both the CCS and the ESC recommends choosing one of the newer oral 
anticoagulants over warfarin for oral anticoagulation, but caution to the fact that there is still 
limited experience with these agents and strict adherence to approved indications and careful 
post-marketing surveillance are strongly recommended (Camm et al., 2012; Skanes et al. , 
2012). 
Demographics. Once the NP has decided with the patient that anticoagulation should 
be started, the demographics in which the patient fits should be considered. Certain 
populations were consistently excluded from the RCTs discussed above, and therefore, we 
cannot predict the therapeutic effect of the new oral anticoagulants in these patients . The list 
is extensive and includes: patients with heart valve disorders , increased risk of bleeding, 
contraindication to warfarin treatment; reversible causes of AF, severe renal impairment, 
active infective endocarditis, active liver disease, known active hepatitis, pregnant women, 
anemia or thrombocytopenia, patients considered not reliable such as those suffering from 
addictions or abusing alcohol, recent stroke or TIA, treatment with ASA >100 mg daily; and 
persistent uncontrolled hypertension. Appendix H outlines the excluded patients. Taking into 
account these exclusions, and the potential for lack of generalizability of the research 
evidence, the NP must make an individualized assessment of the patient demographics and 
consult specialist support if indicated before initiating oral anticoagulation. 
Cost. The NP is very familiar with the situation in which a treatment cannot be 
followed simply because of its cost. As a recent survey of 3,958 Canadians revealed, 15% of 
those interviewed admitted to not filling a prescription or skipping doses due to the cost (The 
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Common Wealth Fund, 2011). As with any new medication, new oral anticoagulants are 
expensive, while warfarin is very affordable. The cost of dabigatran to prevent one stroke per 
year was about four to five times that of warfarin on a European study (Ali et al., 2012). 
Several cost-effectiveness analyses have been done and published since approval of the new 
oral anticoagulants. 
For dabigatran, cost-effectiveness seems to be linked to two factors: stroke risk and 
INR control. The lower the stroke risk, the less cost-effective dabigatran is in comparison to 
warfarin (Shah & Gage, 2011). Conversely, the lower the INR control is, the more cost-
effective it is in comparison to warfarin. For example, in an analysis performed by Shah & 
Gage, for patients with a CHADS2 score of I or 2, warfarin was more cost-effective than 
dabigatran, while for patients with a CHADS2 score of 3 or more, dabigatran 150mg was 
more cost-effective. Dabigatran llOmg was not cost-effective in any situation (Shah & 
Gage). 
Another cost-effectiveness analysis published by some of the same investigators of 
RE-LY in a Canadian context, found both doses of dabigatran highly cost-effective for 
Canadian patients with AF, when prescribing 150mg to patients younger than 80 years old 
and llOmg to patients older than 80 years, based on lower rates of ischemic stroke and 
intracranial hemorrhage (Sorensen et al., 2011) . 
In an American cost-effectiveness analysis in patients with prior stroke or TIA, 
dabigatran 150mg provided 0.36 additional quality-adjusted life-years (QAL Y) at a cost of 
$9,000, and the authors concluded that dabigatran was cost-effective for secondary stroke 
prevention, depending on the adequacy of warfarin management, with greater advantage for 
dabigatran in centers with poor INR control in warfarin treated patients (Kamel, Johnston, 
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Easton , & Kim, 2012b). The same authors performed a cost-effective analysis utilizing the 
same population (AF with previous TIA or stroke) for apixaban and estimated an incremental 
cost-effectiveness ratio (ICER) of $11 ,400 per QALY with apixaban , versus $25 ,000 for 
dabigatran , showing apixaban to be more cost-effective than dabigatran independent of the 
quality of warfarin management in the comparator group (Kamel , Johnston, Easton, & Kim 
2012a). 
Another American cost-effective analysis calculated a cost of $45,372 per QAL Y 
gained with high dose dabigatran compared with warfarin , yielding an additional 0.56 QAL Y 
compared with warfarin in patients> 65 years old with AF and a CHADS2 score ~1 
(Freeman et al., 2011). Alternatively, rivaroxaban has a reported ICER of $27,498 per QAL Y 
gained (Lee et al. , cited in Harrington, Armstrong , Nolan & Malone, 2013). Despite the 
highest cost of all four drugs, one study comparing them found that apixaban has the highest 
QAL Y of all drugs (8 .4 7), providing an additional 0.5 QAL Y at a cost of $7,513, resulting in 
an ICER of $15,026 per QALY gained (Harrington, Armstrong , Nolan , & Malone, 2013). 
Although the overall cost-effectiveness of a drug (including costs related to care after 
severe disability secondary to a stroke) is important for policy making and insurance 
coverage decisions , the patient is usually more concerned about the upfront cost. To assist the 
patient in making this decision, the NP needs to clarify what are the advantages and 
disadvantages of each treatment in relation to its clinical benefits as well as cost. Table 3 
illustrates the yearly cost of therapy with different oral anticoagulants in Canada in 
comparison with the ARR provided by the use of them for stroke rates and major bleeding 
rates. 
Table 3: Estimated yearly cost of anticoagulation therapy and associated ARRs 
Drug 
Warfarin 
(average dose 
5mg/day) 
Dabigatran 
150mg 
Rivaroxaban 
20mg 
Apixaban 
5mg 
Yearly cost 
$273 
$1,963 
$2 ,171 
$3,577 
ARR in stroke 
rates in 
comparison to 
warfarin/year 
NA 
0.58% 
0.3% 
0 .33% 
ARR in major 
bleeding rates in 
comparison to 
warfarin/year 
NA 
0.25 % 
Covered by 
pharmacare? 
Yes 
Special authority 
- 0.2% (bleeding Special authority 
risk increased) 
0 .96% Special authority 
Cost based on retail prices in 2013 in Canadian pharmacies. ARR= absolute risk reduction; 
NA= not applicable. 
For example, a patient treated with dabigatran 150mg in Canada will spend 
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approximately $690/year more than one treated with warfarin. In return he will have a 0 .58% 
ARR in stroke and systemic embolism , meaning that for every 1000 patients taking 
dabigatran 150mg instead of warfarin , approximately 6 strokes will be prevented. Making a 
decision in this case might be very easy if your patient is one of the 6 in a thousand that will 
benefit from spending the extra $690 dollars per year. But since predicting which patients are 
those 6 patients is impossible, the decision to spend this amount of money will have to be 
guided by each individual's financial capabilities and preferences (since cost is only one of 
many variables to be considered). 
Another possibility is a patient with high risk of bleeding , who might not mind paying 
and extra $3 ,000/ year with apixaban to avoid having a major bleeding episode. 
Finally, for some patients , the freedom from constant laboratory monitoring and dose 
adjustments is not measurable in monetary values, and might be worth the increased cost, 
while for others the possibility of a major bleeding episode with no reversal agent at hand 
might also have a real impact that no cost-effectiveness analysis can offset. 
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The NP also has a responsibility to allocate limited resources in health care in a way 
that will benefit the most people for the lowest cost. For example, as Shah and Gage (2011) 
point out, prescribing dabigatran even when it would not be cost-effective (i.e. patients with 
TTRs > 70%, or with low CHADS2 score) would increase costs with modest health benefits, 
more dyspepsia and possibly more Mis than warfarin , possibly worsening health. In British 
Columbia (BC) dabigatran, rivaroxaban and apixaban are covered by Pharmacare for stroke 
prevention in patients with non-valvular AF in whom anticoagulation is inadequate following 
2-month trial on warfarin, or patients for whom anticoagulation using warfarin is 
contraindicated or not possible due to inability to regularly monitor the patient via INR 
testing (Ministry of Health, 2013). 
In summary, cost is an important variable that the NP needs to consider in order to 
determine which therapy will provide the most benefit for the best cost, considering each 
individual's stroke risk, bleeding risk, warfarin management, financial situation, prescription 
coverage and preferences. 
Adherence. No therapy can be efficacious if the patient is unable to adhere to it. 
Adherence to warfarin has been historically challenging due to the constant dose adjustments, 
monitoring and bleeding risk. Furthermore adequate INR depends on the patient's ability to 
adhere not only to the medication, but also to regular monitoring and dietary restrictions. 
Nevertheless warfarin is , for most patients, associated with relatively limited impact on 
quality of life and the ability to carry out daily activities (MacLean et al., 20 12), and a missed 
dose is usually of no consequence in therapeutic INR, due to the long half-life of the drug. 
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Adherence with the newer drugs might be easier for patients who find dose 
adjustments , monitoring and dietary restrictions of warfarin treatment too cumbersome. But it 
is important to consider that both dabigatran and apixaban are dosed twice daily, which might 
be more difficult for some patients to remember. Furthermore, missing one dose of any of the 
newer anticoagulants can be highly detrimental to treatment, due to the short half-life of 
them. Therefore, the NP needs to emphasize the importance of adherence to treatment, be it 
with warfarin or one of the new oral anticoagulants , discussing with each patient their 
perceived barriers and limitations for adherence and providing coaching to support optimal 
self-management. It is according to those perceptions that a better plan can be developed, 
individualized for each patient's situation. 
Safety and side-effect profile. Of all the new oral anticoagulants, we know that 
apixaban offered the greatest ARR in major bleeding (0.96%, vs 0.25 % for dabigatran 
150mg) and that rivaroxaban caused a small increase in major bleeding (0.2%) despite a 
similar decrease in intracranial bleeding (0.2%) in comparison to warfarin. The NP should 
also consider that gastrointestinal (GI) bleeding was considerably higher with dabigatran and 
rivaroxaban than with warfarin , and that apixaban had lower GI bleeding rates than warfarin. 
Recent post marketing surveillance on dabigatran has revealed numerous reports of major GI 
bleeding (Institute for Safe Medication Practices , cited in Ogbonna & Clifford, 2013). 
Therefore, in patients with GI bleeding predisposition , warfarin or apixaban might be safer 
options. 
A history of ACS and predisposition for MI (for example smokers, with a family 
history of Ml) might be another consideration. We know from trial data that there might be a 
small correlation in use of dabigatran and incidence of MI (although the data is conflicting as 
previously discussed). No such correlation has been found with rivaroxaban, apixaban or 
warfarin, making all three drugs safer alternatives in this group of patients . Furthermore, 
usually these patients are on antiplatelets , which are known to increase bleeding risk with 
anticoagulants, especially warfarin . Therefore , choosing an anticoagulant with a lower 
bleeding risk profile, such as apixaban , might be reasonable in such context. 
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Dabigatran has been associated with significantly higher discontinuation due to 
dyspepsia (Paikin et al., 2011). Therefore , the NP can consider another anticoagulant in 
patients known to have predisposition for stomach discomfort, such as a history of gastro-
esophageal reflux. Since these drugs are new, it is also important to keep a healthy degree of 
suspicion for side effects that might not have been documented in the literature yet. 
Therefore, a comprehensive patient assessment in addition to close monitoring of patients 
being treated with new oral anticoagulants is warranted. The NP is uniquely positioned to 
provide this , given their holistic focus and patient-centred management approach. 
Drug-drug and food interactions. New oral anticoagulants have low propensity for 
drug-drug and food interaction, while warfarin is known to interact with a number of agents. 
Although it is possible to adjust the warfarin dose to each patient and avoid complications 
from such interactions, in some cases where adjustment is difficult, the NP might prefer one 
of the newer agents , with a smaller list of possible interactions. Nevertheless, the NP should 
monitor for interactions that might not have been documented yet, and choose therapy 
keeping in mind the ones that are already known . 
For example, dabigatran absorption is decreased with proton pump inhibitors (PPis), 
and it might be prudent to choose another agent for patients that require PPis , also taking into 
consideration that dabigatran increases GI bleeding risk , which these patients might be more 
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prone to developing. Careful consideration of dose should be exercised when dabigatran in 
coadministered with P-gp inhibitors such as amiodarone and verapamil, while the 
concomitant use of the P-gp inducer rifampin in contraindicated (Boehringer Ingelheim 
Canada, 2012) 
For rivaroxaban and apixaban, caution is necessary with potent 3A4 and P-
glycoprotein inhibitors such as ketoconazole, clarithromycin and ritonavir, since they 
augment the anticoagulation effect. Concomitant use of antiplatelets and NSAIDs increases 
bleeding risk with all oral anticoagulants, and considerable care should be taken when 
prescribed together. To manage this effectively , the NP must provide education and support 
to enable the patient to optimize their outcomes and identify potential complications and 
interactions. 
Anticoagulation reversal. Unfortunately, as previously discussed, there are no 
anticoagulation reversal agents available for the new oral anticoagulants at the moment, and 
this causes significant concern among patients and providers. Various strategies have been 
suggested, such as monoclonal antibodies and molecular decoys; however, their availability 
is not expected any time in the near future (Kaatz & Crowther, cited in Ogbonna & Clifford, 
2013). 
The NP needs to carefully consider the bleeding risk of each patient and discuss this 
limitation with him. In one hand , new oral anticoagulants are of advantage for patients with 
increased bleeding risk, because the trials have shown decreased rates of major bleeding, 
especially intracranial bleeding. On the other hand , one might be concerned and careful in 
prescribing an anticoagulant with no reversal agent to a patient known to be at increased risk 
of bleeding because of the lack of a reversal agent. 
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There is no clear answer and this is a question that might be solved only after reversal 
agents are developed and studied. Meanwhile the NP will need to take both perspectives to 
the patient before making a decision, since each case is different and this is only one of the 
many variables to be considered. In case of bleeding episodes with one of the new oral 
anticoagulants, strategies such as temporary discontinuation of the drug, mechanical 
compression and hemodynamic support have been suggested (Maan et al. , 2012). A 
comprehensive assessment and ongoing monitoring by the NP is warranted. 
Renal Impairment. AF patients with severe renal failure are at high risk for stroke, 
but are also at increased risk for death, coronary events and serious bleeding. Unfortunately, 
patients with renal impairment have not been adequately studied and have been excluded 
from clinical trials , and their risk assessment is complex (Marinigh , Lane, & Lip cited in 
ESC, 2012). Furthermore, all new oral anticoagulants have a certain degree of renal 
excretion. 
Despite renal impairment and renal clearance being considered a minor determinant 
of anticoagulant response to warfarin (Bristol-Myers Squibb Canada, 2011), the safety of 
warfarin in this population is not well established and the Kidney Disease Improving 
Outcome authors have advised that , pending further data , "routine anticoagulation of dialysis 
dependent chronic kidney disease patients with AF for primary prevention of stroke is not 
indicated" (Herzog, Asinger, Berger, et al. , cited in Skaneset al. , 2012) . 
Of all the new oral anticoagulants , apixaban is the one with the safer renal profile, 
since the kidneys excrete only approximately 25 % of the drug (Hohnloser et al., 2012) in 
comparison with one third for rivaroxaban and 80% for dabigatran. Data is missing for 
patients with CrCl < 30ml/min for dabigatran and rivaroxaban , and <25mg/min for apixaban, 
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and the risk of anticoagulating these patients not always outweigh the benefits, especially if 
they are on dialysis. Oral anticoagulation in the context of severe renal impairment is an 
example of a situation outside the NP's scope of practice in which a specialist should be 
consulted, as outlined by the CRNBC (2012): the NP consults with or refers to physicians 
when the client's health condition or needs are such that the anticipated outcomes of therapy 
are not realized and further treatment is beyond the ability of the NP to manage. Therefore 
the NP should defer the decision of anticoagulation in these patients to a nephrologist or 
other specialist. 
The NP should monitor renal function of patients being anticoagulated before 
initiation of therapy, and regularly after that since renal function may not remain static, 
especially in elderly patients with multiple comorbidities and concomitant drug therapies 
(ESC, 2012). The ESC recommends assessing renal function annually in patients with normal 
(CrCl ~80 mL/min) or mild (CrC150-79 mL/min) renal impairment, and perhaps 2-3 times 
per year in patients with moderate renal impairment (i .e. creatinine clearance 30-49 
rnL/min). 
Renal function is just another of the many factors that the NP will need to consider 
before selecting appropriate anticoagulation for patients with AF, and as with the previous 
issues discussed in this analysis, each decision will have to be tailored to the specific context 
and needs of each individual patient. As the primary health care providers of complex 
patients with multiple chronic illnesses and comorbidities, the NP will need to carefully 
assess the renal function in any patient being considered for anticoagulation therapy, as well 
as provide ongoing renal function monitoring. 
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Age. Age is an important consideration for the NP when choosing appropriate 
anticoagulation, especially considering that the prevalence of AF increases with age. 
Medication compliance, polypharmacy, and mobility difficulties are common issues with the 
elderly, and can influence the quality of the anticoagulation therapy. For example, with the 
many drug-drug interactions that warfarin has, it can be difficult to achieve therapeutic INR 
in patients who are on several different medications. 
Moreover, elderly patients are more frequently prone to acute episodes of intercurrent 
diseases (such as infections or heart failure , that are commonly associated with a rapid 
worsening of the renal function), frequent changes in medications and dietary sources of 
vitamin K (Pengo et al. 2012; Zarraga & Kron , 2013). These issues can also make it more 
difficult for the elderly to adhere to monitoring, dosing adjustments and dietary restrictions 
with warfarin, and more difficult to achieve therapeutic INRs. Dementia and impaired 
cognition -which are also more common with aging - can worsen adherence, which can be 
detrimental especially with the new oral anticoagulants due to their short half-life. 
The elderly are also more prone to injury due to falls, which can have more serious 
consequences, such as an intracranial bleeding after a minor injury to the head. Nevertheless, 
the benefits of anticoagulation is this group have been demonstrated. For example, in 
individuals who were at high risk of falls but were also on moderate risk for a stroke 
(CHADS2 ~2), warfarin was associated with a 25 % relative risk reduction in the composite 
outcome of stroke, intracranial hemorrhage, MI , and death (Zarraga & Kron, 2013). 
Therefore, anticoagulation in the elderly is still recommended and the NP should 
identify all the possible issues and foresee the associated barriers to proper anticoagulation in 
order to choose the appropriate therapy. It is especially important to consider the whole 
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context in order to make an appropriate recommendation. For example, what type of support 
network is available, who is assisting the patient with daily activities and decision-making, 
what type of financial support is available, what types of other medications is the patient on 
and what other medical issues exist, how difficult is it to get to the laboratory for monitoring 
and to come to office visits, what is their renal function like, etc. 
In terms of safety profile and convenience of use , new oral anticoagulants can be a 
good choice for patients older than 75 years old. As we know, these patients are at increased 
risk of intracranial bleeding, and that risk is lower with new oral anticoagulants than with 
warfarin. Also, since there is no need for monitoring and dose adjustments, it might be easier 
to adhere to therapy. 
The efficacy of dabigatran was no different among patients aged< 75 years and those 
::::: 75 years, but because 150 mg doses of dabigatran may cause more major bleeding among 
patients older than 75 years, the Canadian Cardiovascular Society recommends prescribing 
dabigatran at 110 mg (Skanes et al., 2012). The FDA on the other hand concluded that any 
benefit-risk assessment in which stroke and systemic emboli are given more weight than 
nonfatal bleeding events, would find the higher dose more favorable in the elderly patients, 
and ultimately approved only the 150mg strength (Beasley et al., 2011). Both doses are 
available in Canada. 
For both rivaroxaban and apixaban, efficacy against stroke and systemic embolism 
and safety for the avoidance of major hemorrhage is not significantly different between 
patients < 7 5 years and those ::::: 7 5 years (Patel et al., 2011, Granger et. al. 2011). 
As previously discussed , renal function tends to deteriorate with aging, and in such 
patients warfarin might be a better choice, or reduced dose apixaban if the CrCl is still 
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>25ml/min. Choosing appropriate anticoagulation therapy for the elderly is clearly not a 
simple decision. The NP should consider all the variables discussed, keeping in mind the 
need to work with other specialists and involve other members of the interdisciplinary team 
such as social work, occupational therapists, nutritionists , home care and community 
resources when necessary and available . 
Coronary artery disease. The indication and use of anticoagulation in CAD and 
ACS merits its own analysis and it is not the purpose of this review to accomplish that. 
Considering that AF can be a common occurrence with CAD, a few recommendations will be 
briefly explored. 
There is good RCT evidence for the use of aspirin, clopidogrel, combination aspirin 
plus clopidogrel, and warfarin for patients with various manifestations of CAD, but no RCTs 
have specifically addressed anti thrombotic management of patients with AF who also have 
CAD (Becker, Meade, Berger, et al., cited in Skanes et al. 2012). 
The ESC (2012) recommends triple therapy (oral anticoagulation plus two 
antiplatelets) immediately after ACS, followed by a period of dual therapy (oral 
anticoagulation and one antiplatelet), and after one year, dose-adjusted warfarin , dabigatran, 
rivaroxaban or apixaban, but they recognize the lack of data about triple therapy with new 
oral anticoagulants . The CCS recommends the use of dabigatran , rivaroxaban or apixaban in 
preference of warfarin, but recognizes that these recommendations derive from extrapolations 
of available RCTs, and that further research in this area is needed (Skanes et al., 2012). 
All oral anticoagulants have higher bleeding rates when used in combination with 
antiplatelets and to further obfuscate the matter, the scientific evidence is not clear on how to 
appropriately use them in this context and further research is needed. The NP should, 
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whenever available, involve the expertise of a cardiologist for complex patients that need the 
combination of antiplatelets and oral anticoagulation in CAD and ACS. 
Other limitations. In addition to the limitations discussed above , the NP needs to be 
aware of other potential issues related to some specific demographics. For example, neither 
warfarin, dabigatran, rivaroxaban nor apixaban can be used during pregnancy. Warfarin is 
known to be teratogenic (Bristol-Myers Squibb Canada, 2011) , and there is no data for the 
other three, since pregnant patients were excluded from the RCTs. Warfarin appears to be 
safe during lactation and can be used with caution (Bristol-Myers Squibb Canada). 
The new oral anticoagulants are protein bound and dose adjustments might be 
necessary during acute inflammation , because of reduced synthesis of serum albumin and 
increased catabolic state (Thethi et al. , 20 12). Patients with hepatic impairment were 
excluded from RCTs with the new oral anticoagulants and data is limited for this patient 
population. Warfarin remains a safer alternative for this group of patients. Having awareness 
of these special populations is critical for the NP who may be exposed to a wide population 
of patients with diverse clinical needs and profiles. 
In summary , this analysis has presented a critical discussion of the clinical literature 
related to the prevention of stroke in those with non-valvular AF, as well as assessed the 
literature in relation to wider contextual and patient factors including risk, demographics, 
cost, adherence , safety and side-effect profile, drug-drug and food interactions , 
anticoagulation reversal, renal impairment, age, coronary artery disease, and other limitations 
need to be carefully reviewed with the patient. The NP can only make an appropriate 
decision with the patient by fully disclosing the advantages, disadvantages , barriers and 
limitations of the available options, as well as considering the patient's preferences, values 
and beliefs. 
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This chapter also contrasted the clinical trial data available for warfarin, dabigatran, 
rivaroxabam and apixaban to the variables explained above, making objective and concise 
recommendations for the NP to use in clinical practice. Although the RCTs discussed above 
have offered encouraging results, there are still many questions unanswered. For example, 
long-term effects of therapy are not clear and their safety outside of clinical trial 
environments is not yet well known. The lack of reversal agents and appropriate laboratory 
monitoring remain a challenge. The following section discusses the role of new oral 
anticoagulants in clinical practice and offers specific recommendations for NPs in primary 
care. 
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Chapter IV 
Discussion 
Stroke is the second leading cause of death worldwide and is a chief cause of serious, 
long-term adult disability (Lloyd-Jones, Adams, Brown, et al., cited in Nguyen, Yacoub , 
Chan , & Quach, 2012). This project has analyzed and discussed the data and evidence 
available for the use of oral anticoagulants in non-valvular AF for stroke prevention in adults, 
and has identified some key considerations for the NP when choosing the most appropriate 
anticoagulation therapy. 
The results were encouraging. New oral anticoagulants offered similar efficacy in 
stroke and systemic embolism prevention as warfarin, with lower intracranial bleeding rates 
and easier handling, since they do not require regular monitoring or dose adjustments, and 
have very few known drug interactions. Dabigatran and apixaban, were found superior than 
warfarin for stroke prevention , while apixaban showed a superior safety profile in regards to 
major and intracranial bleeding. 
Nevertheless , as it was discussed in this project, several limitations exist to the use of 
such agents. As Vassiliou & Flyn (2012) put it: 
For all the problems associated with warfarin, they are at least well known. To 
manage the thromboembolic risks associated with atrial fibrillation, often years, even 
decades, of treatment are needed; so long-term safety data for all novel oral 
anticoagulants are necessary, as exemplified by ximelagatran, which was withdrawn 
after long-term follow up revealed an increased risk of liver toxicity. (Vassiliou & 
Flynn , 2012 , p.1719) 
The lack of a reversing agent, the high cost of therapy, the lack of data in certain 
populations (i.e. severe renal impairment), the increased rate of GI bleeding (with dabigatran 
and rivaroxaban), and the several critiques to methodologies of the available RCTs highlight 
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the need for more data and research, as well as considerable caution by the NP when using 
these new agents . 
The Role of New Agents in Clinical Practice 
After considering all the clinical implications discussed above and identifying the 
context, values and preferences of each patient, the NP will need to make a decision with the 
patient about which agent to use. New oral anticoagulants were developed based on a need 
identified in the market. Although highly effective, warfarin therapy is cumbersome, 
adherence and compliance are difficult , and food and drug interactions are frequent. 
Although the RCTs discussed above have offered encouraging results, there are still many 
questions unanswered. For example, long-term effects of therapy are not clear and their 
safety outside of clinical trial environments is not yet well known. 
Table 4: Examples of patients who might benefit from therapy with new oral anticoagulants, 
for stroke prevention in non-valvular atrial fibrillation 
Patients living in remote areas with no access to laboratory services and therefore 
unable to monitor INR and adjust warfarin accordingly; 
Patients in which INR target has been difficult to achieve; 
Patients who need other medications which interact with warfarin, provided they do 
not interact with the agent chosen; 
Patients with severe mobility restrictions who cannot go to the laboratory and clinic 
for frequent INR testing and appointments ; 
Frequent travelers; 
Patients who have difficulty complying with warfarin therapy. 
* Provided that they do not have any contraindications to dabigatran and do not belong to one 
of the populations not included in the RE-LY, ROCKET or ARISTOTLE. 
It is also important to keep in mind that the RCT results previously discussed apply 
only to patients with at least one additional risk factor for thromboembolism in addition to 
AF. Therefore, the role of the new oral anticoagulants in patients with AF and no other risk 
factors is not clear and their use in practice has to be carefully considered by the NP. While 
new agents show great promise, warfarin still has great advantages and remains an effective, 
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affordable, safe, well studied, well known alternative, which can be safely used by the NP in 
most scenarios. New oral anticoagulants might offer an advantage in patients who might 
benefit from some of their features previously discussed (i.e . decreased intracranial bleeding 
risk, less drug-drug interactions, convenience of use , etc.) or who for some reason cannot 
tolerate warfarin therapy. Table 4 summarizes a few examples of patients who might benefit 
from anticoagulation with one the new oral anticoagulants , considering that they do not fall 
into a population demography that has not been studied, and table 5 lists a few examples of 
patients who might benefit from therapy with warfarin, versus a new oral anticoagulant. 
As new research and new agents are developed, the role of new oral anticoagulants in 
clinical practice will become clearer. Meanwhile, as the ESC (2012) cautions: "Clinicians 
should remain aware that clinical experience with these agents is still limited and that care, 
vigilance and further information on their effectiveness in clinical practice are needed." 
Table 5: Examples of patients who might benefit from therapy with warfarin vs new oral 
anticoagulants for stroke prevention in non-valvular atrial fibrillation 
Patients who have been successfully treated with warfarin before and have high 
TTRs; 
Cognitively high functioning patients, in whom compliance, monitoring and dose 
adjustments are expected to go well; 
Patients at increased risk for gastrointestinal bleeding; 
Patients with liver impairment; 
Patients with no medication coverage and low income, or unable/unwilling to pay for 
a more expensive therapy; 
Patients in which reversal of anticoagulation is a desirable feature. 
Recommendations 
NPs are in a privileged and opportune position to assist the patient with AF. They can 
bring valuable information and education to patients and families, assess stroke and bleeding 
risks, collaborate with the interdisciplinary team, discuss available therapeutic options with 
the patient and implement them. While new oral anticoagulants are comparable to warfarin in 
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terms of efficacy and safety, and can be of assistance and benefit in some situations, they still 
offer some limitations that the NP needs to consider, and not every patient in warfarin can 
automatically be switched to one of the new agents. Figure 3 summarizes the key findings 
and recommendations in this review. 
The NP should be aware of all the benefits and limitations of both warfarin and new 
oral anticoagulants, and be able to discuss with each patient what features are desirable of 
each therapy and what applies to their context. Issues such as cost, convenience, bleeding 
risk, adherence, anticoagulation reversion, age, concomitant illnesses and drug use were 
thoroughly discussed in this analysis and should be carefully considered and discussed with 
the patient before choosing a therapy. 
The NP should involve the interdisciplinary team when possible and when necessary 
to assist in delivering the best available evidence based therapy for the patient and to assist 
with issues that typically impact compliance and adherence, such as mobility, cognition 
impairment and lack of financial and social support. Professionals such as specialists, nurses, 
occupational therapist, nutritionists and social workers can offer assistance with several of 
the issues that impose barriers to appropriate anticoagulation therapy. 
It is fundamental that NPs understand that the complexity of choosing anticoagulation 
therapy exceeds raw data of clinical trials, and involves social and economical contexts, 
personal beliefs , values and preferences. Patient selection and management strategies are a 
cornerstone of patient care , and the introduction of alternatives to vitamin K antagonists 
should not change a time-honored tenet designed to minimize risk and maximize benefit 
(Wisler & Becker, 2012). 
Education and research. The issue of oral anticoagulation is one that is constantly 
being revisited as new research and new therapies continue to emerge. The NP will need to 
stay current in new developments , anticipating that new therapies will emerge and looking 
for new data on the long-term safety of the drugs that are already in use. Furthermore, 
developments in some of the issues that were discussed , such as lack of reversal agent and 
laboratory monitoring, are expected, and the NP should strive to stay current with these. 
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Patient education is also fundamental for proper management of stroke risk in AF. It 
has been demonstrated that NPs are successful in utilizing patient education to improve 
outcomes and treatment adherence in chronic illness (Allen et al. , 20 11 ; Hayes, 2007). 
Ultimately, education is the most effective intervention that the NP can offer. It improves 
adherence, addresses risk factors and improves outcomes. The NP should always make 
patient education a priority. 
Further research and head-to-head comparisons, as well as careful post-market 
surveillance are necessary to further understand the role, use, side effects and impact of new 
oral anticoagulation in practice. Meanwhile, the NP can use the information provided in this 
analysis to carefully assess the situation of each patient, discuss the options with him and 
choose an appropriate anticoagulation therapy that is evidence-based and tailored to each 
patient's specific needs . Discussing options and offering choices to the patient is the only 
way that the NP can ensure the best result possible, by actively engaging each person in their 
own care and sharing the responsibility with them. This project offers valuable data to allow 
NPs to have such important and fundamental discussions with their patients. 
Figure 3: Key findings and recommendations . 
For clinical practice: 
1. Always assess stroke and bleeding risk before deciding oral anticoagulation using 
a validated tool such as the CHA2DS2-V ASC score 
2. Initiate oral anticoagulation in patients with AF and at least one risk factor. 
3. Choose an agent after disclosing and discussing all the risks and limitations of the 
therapies available with the patient. 
4 . Dabigatran, rivaroxaban and apixaban are comparable to each other for stroke 
prevention, while only dabigatran 150mg and apixaban were superior to warfarin, 
and only apixaban was superior to warfarin in patients with TTR ;:: 70%. 
5. New oral anticoagulants were associated with a significant reduction in the rate of 
major bleeding events. But this advantage is offset by the Jack of a reversal agent 
for those patients that do bleed. 
6. The long safety track record and high efficacy of warfarin make this therapy still 
an appropriate choice for most case scenarios. 
7. New oral anticoagulants are best reserved for patients who for some reason 
cannot tolerate warfarin, or who can benefit from one of the features offered by 
the new oral anticoagulants until more data about their safety is available. 
8. Dabigatran is associated with increased risk of GI bleeding and possible increased 
MI rates. The NP should choose an alternative treatment for patients at increased 
risk. 
9. Data is insufficient to recommend treatment with any of the new oral 
anticoagulants in patients with renal or hepatic impairment, or CAD, and the NP 
should involve a specialist in this decision . 
10. Therapy with new oral anticoagulants is significantly more expensive than 
warfarin although cost effective for patients with low TTRs or higher stroke risk. 
11 . When using anticoagulation in the elderly the NP should identify associated 
barriers to proper anticoagulation in order to choose the appropriate therapy. 
For research 
12. Further research is needed to validate these initial results, especially in patients 
with well controlled INRs and who are not using antiplatelets. 
13. Long term data is lacking for the new oral anticoagulants, making it difficult to 
clearly determine their safety profile and interactions. Vigilance and a high 
degree of suspicion for adverse events is warranted when using these agents. 
14. Further research and head-to-head comparisons, as well as careful post-market 
surveillance are necessary to further understand the role, use, side effects and 
impact of new oral anticoagulation in practice 
For education 
15 . NPs need to stay current with the new research and data that is expected to 
emerge about oral anticoagulation, since new agents, reversal agents and 
laboratory monitoring are expected 
16. NPs should offer education about the use of oral anticoagulation to every patient 
eligible to receive them , in order to improve adherence and outcomes. 
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Conclusion 
AF remains a serious concern in primary care, affecting 1% of all adults, with an 
increasing prevalence in the elderly, ranging from nearly 4% in persons 60 years old or older, 
to 9% of individuals aged 80 years old or older (Go et al., 2001). It continues to impose an 
unacceptably high risk of disability, and death related to stroke risk. In fact , ischemic strokes 
in association with AF are often fatal, and continue to be a leading cause of death in Canada. 
Furthermore , those who survive are left more disabled by their stroke and more likely to 
suffer a recurrence than patients with other causes of stroke (ESC, 2010). Considering an 
aging population in Canada, and increasing complexity and comorbidities, the NP is in a key 
position to impact the outcomes associated with AF. 
NPs provide client education, support health promotion, involve clients in care and 
follow practice guidelines (Barr, Johnston, & McConnell, cited in CNA, 2009). NPs are able 
to play a key role in stroke prevention of patients with AF, by offering timely advice, 
information, education and assisting the patient in defining risks , examining options 
available, connecting with the interdisciplinary team and implementing appropriate therapy 
tailored to each individual 's context and risk assessment. 
The question of appropriate stroke risk management in AF is complex, and the 
clinical decision-making process needs to encompass several aspects and variables not only 
about therapeutic choices, but also about the patient's context and preferences . To assist the 
NP in making such a complex decision , this project conducted a literature review and 
presented the evidence that exists for the use of the oral anticoagulants currently available for 
stroke prevention in nonvavular AF, critically analyzing the data and offering clinical 
recommendations for practice. 
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Since the decision of which treatment to use is complex and involves much more than 
looking at raw clinical data, this project conducted a thorough discussion of many of the 
variables that the NP will need to consider when discussing options with the patient suffering 
with AF. Two main key themes were thoroughly discussed and critically analyzed: 
pharmacological management and clinical decision-making. 
For the pharmacological management analysis three new oral anticoagulants were 
reviewed and discussed in this project: the direct thrombin inhibitor dabigatran and two 
factor Xa inhibitors- rivaroxaban and apixaban. They were all contrasted with warfarin and 
the RCTs available were thoroughly reviewed and appraised. In summary, all of them offered 
efficacy at least similar to warfarin , and dabigatran and apixaban were found to be superior to 
warfarin. All of them offered similar bleeding risk as warfarin, with decreased intracranial 
bleeding, but dabigatran and rivaroxaban were associated with higher GI bleeding rates . 
Nevertheless, the RCTs are not free of critiques that could have biased the results, such as 
high rates of aspirin use and low TTRs for warfarin, and one of the studies was criticized for 
being open-label (the RE-LY trial). New agents show great promise and potential, but have 
limited amount of data available , while warfarin has 50 years of use and research available. 
Further research, careful post-market surveillance and long-term data will help clarify and 
understand the role of new oral anticoagulants in practice. 
Next this review carefully analyzed implications for clinical decision-making. Eleven 
themes emerged for consideration in clinical decision-making: 1) risk, 2) demographics, 3) 
cost, 4) adherence, 5) safety and side-effect profile, 6) drug-drug and food interactions, 7) 
anticoagulation reversal, 8) renal impairment, 9) age, 10) CAD, and 11) other limitations. 
Each theme was carefully discussed, with specific recommendations provided for NPs in 
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clinical practice. The importance of assessing risk and deciding the need for oral 
anticoagulation with the patient was highlighted. This decision should be made with the 
patient, after discussing and determining both stroke and bleeding risks. It is fundamental 
that the NP assesses and compares the risk of stroke with the risk of bleeding. A shared 
decision should be made with the patient after disclosing all the associated risks, advantages 
and disadvantages of the treatments available, and carefully discussing each of the themes 
mentioned above. The lack of reversal agents and laboratory monitoring for the new oral 
anticoagulants remain considerable limitations to their use in clinical practice and patients 
should be aware of the risk of bleeding. 
It is also paramount that the NP discusses and considers the individual context of each 
patient, such as financial situation and prescription coverage, limitations associated to age 
and other comorbidities. Whenever possible, the NP should involve the interdisciplinary team 
in the care of the patient with AF, to improve outcomes and address issues known to impact 
therapy, such as financial insecurity, mobility issues, and food insecurity to name a few. 
Although oral anticoagulation in AF falls within the scope of NPs, there are certain situations 
as discussed above, where this is not the case (i .e. concomitant renal impairment, triple 
therapy or any other situation in which the NP feels a decision is beyond her skills and 
judgment). In these situations, the NP should refer to a specialist or seek consultation. 
This review provided the NP with valuable insight and information to make an 
informed decision with the patient to safely and efficiently manage stroke risk in AF. The 
decision is not a simple one, and will demand careful consideration, close monitoring and 
vigilance, in spite of the therapy chosen. Constant education and health promotion remain 
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fundamental for good outcomes and the NP has a key role in promoting that. Furthermore, as 
new research and data become available, this issue will need to be revised and updated. 
In summary, as this review showed, oral anticoagulation remains a key aspect in 
stroke risk management for patients with AF. In terms of pharmacological management 
warfarin remains a safe, effective and affordable therapy, which can still be used in most case 
scenarios . Meanwhile dabigatran , rivaroxaban and apixaban, offer a much-needed alternative 
for those patients that cannot tolerate warfarin therapy , due to its many difficulties and 
inconveniences of use. However, they are not free of limitations and those need to be 
carefully considered by the NP. It is expected that new research will be able to address some 
of these limitations, such as the lack of reversal agent and laboratory monitoring tests. The 
NP is in a key role to improve outcomes in this population, by carefully managing and 
monitoring stroke and bleeding risk in the patients with AF, discussing therapies available 
and their limitations, offering education, closely monitoring and always involving the patient 
in the decision-making process. 
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Potential Causes of Atrial Fibrillation 
Cardiac causes: 
- Hypertension 
-Heart failure 
Appendix A 
- Coronary artery disease with prior myocardial infarction 
-Left ventricular dysfunction (systolic and diastolic) 
- Hypertrophic, dilated, and restrictive cardiomyopathies 
- Valvular heart disease 
- Congenital heart disease (early repair of atrial septal defect) 
- Pericardia! disease 
-Postsurgical (particularly cardiac surgery) 
- Sick sinus syndrome 
- AF as a result of ventricular pacing 
- Supraventricular tachycardia (including Wolff-Parkinson-White syndrome, atrial 
tachycardia, atrial flutter, or other) 
- Genetic/familial 
Noncardiac causes: 
- Obstructive sleep apnea 
-Obesity 
- Excessive alcohol ingestion (acute or chronic) 
- Hyperthyroidism 
- Vagally mediated (ie., habitual aerobic training) 
- Pulmonary disease (pneumonia, chronic obstructive pulmonary 
disease, pulmonary embolism, pulmonary hypertension) 
-Lone (idiopathic) AF 
Adapted from CCS (20 I 0) 
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Appendix B 
The coagulation cascade and thrombus formation 
Vessel Damage 
fibrinogen 
monomers 
Platelet adherence 
88 
Platelet aggregation 
( Blood clot J 
The coagulation cascade and thrombus formation. Vessel damage leads to platelet 
aggregation and a cascade of events, with each coagulation factor converting the next factor 
to it's activated form (represented by the a), until fibrin is produced and a blood clot is 
formed . Observe the central role of thrombin (FII) for clot formation . TF=tissue factor; 
F=factor. 
Appendix C 
The HAS-BLED scoring system for risk of bleeding on oral anticoagulation therapy 
Bleeding risk- HAS-BLED score 
Clinical characteristic Points 
Hypertension 1 
Abnormal liver or renal 1 or 2 (1 point each) 
function 
Stroke 1 
Bleeding 1 
Labile INRs 1 
Elderly (age >65 years) 1 
Drugs or alcohol 1 or 2 ( 1 point each) 
Source: Pisters, Lane, Nieuwlaat, et al. , cited in Cairns (2012a) . INR= international 
normalized ratio 
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Appendix D 
The CHADS2 risk score adjusted stroke rate 
CHADS2 score Adjusted stroke rate, %/year 
(95% Confidence Interval) 
0 1.9 (1.2 to 3.0) 
1 2.8 (2.0 to 3.8) 
2 4.0 (3.1 to 5.1) 
3 5.9(4.6to7.3) 
4 8.5 (6.3 to 11) 
5 12.5 (8.2 to 17.5) 
Source: Gage et al. cited in Bashore et al. (20 13) 
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Appendix E 
Search strategy flow chart 
ACS= acute coronary syndrome, VTE= venous thromboembolism 
Appendix F 
Pros and Cons of warfarin and new oral anticoagulants 
Therapy 
Pros 
Cons 
Warfarin 
Long safety track (in use for over 50 
years); 
Anticoagulation can be titrated to 
each individual bleeding risk and 
response to the drug, guided by blood 
monitoring; 
Drug and food interactions are well 
known and studied; 
Highly effective for stroke prevention 
in atrial fibrillation; 
Reversal agents are available and 
effective; 
Compliance can be monitored and 
appropriate education about risk 
prevention can be given. 
Not contraindicated in renal or 
hepatic diseases 
Once a day dosing 
Low cost 
Has multiple drug and food 
interactions; 
Needs regular laboratory monitoring 
and dose adjustments to maintain 
efficacy (narrow therapeutic index); 
Has a long half-life , and needs 
several days before full effect after 
therapy initiation or before therapy 
discontinuation; 
Requires frequent office visits and 
education for proper use. 
Bleeding risk is increased , but 
usually stroke risk offsets bleeding 
risk. 
New oral anticoagulants 
Efficacy comparable to warfarin for 
stroke prevention ; 
Few known drug interactions and low 
potential for food and drugs 
interaction; 
Convenient fixed dose therapy with 
no need for regular monitoring; 
Once a day dose for rivaroxaban; 
Apixaban (but not dabigatran or 
rivaroxaban), has lower major 
bleeding risk than warfarin; 
Less intracranial bleeding; 
Short half-life and fast onset of action 
for therapy initiation and therapy 
discontinuation ; 
New drugs, long term effects not 
fully understood yet; 
No available method to monitor 
anticoagulation intensity or to titrate 
therapy to each individual; 
Drug and food interactions not fully 
known; 
No reversal agents available; 
Bleeding risk is increased, but 
comparable to warfarin; 
More GI bleeding risk with 
dabigatran and rivaroxaban than 
warfarin; 
Small and possibly nonsignificant 
increase in MI risk with dabigatran. 
Limited data for use in renal and 
hepatic diseases 
Twice a day dosing for dabigatran 
and apixaban; 
Inability to monitor treatment 
compliance by blood work 
New oral anticoagulants= dabigatran , rivaroxaban and apixaban. 
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Appendix G 
Projected outcomes per year in a theoretical population with AF being treated with dose 
adjusted warfarin versus dabigatran 150mg BID for one year versus rivaroxabam 20mg OD 
and apixaban 5mg BID 
Outcome Warfarin 
Stroke or 
systemic 
embolism 
Myocardial 
infarction 
Death from any 
cause 
N= 1000 
16-24 
5-9 
39-45 
Dabigatran 
150mg 
N= 1000 
11 
7 
36 
Rivaroxabam 
N= 1000 
21 
11 
49 
Adapted from: Connolly et al. (2009), Petel et al. (2011). 
Apixaban 
N= 1000 
12 
5 
35 
Appendix H 
Examples of populations excluded from the RE-LY, ROCKET AND AVERROES trials 
Populations not studied. Patients with: 
o Heart valve disorders 
o Conditions associated with an increased risk of bleeding 
o Contraindication to warfarin treatment 
o Reversible causes of AF 
o Severe renal impairment (estimated creatinine clearance =::;30 mL/min); 
o Active infective endocarditis; 
o Active liver disease; 
o Known active hepatitis C (positive HCV RNA); active hepatitis B (HBs antigen+, 
anti HBc lgM+ ); or active hepatitis A; 
o Persistent uncontrolled hypertension (SBP >180 mm Hg or DBP >100 mm Hg); 
o Pregnant women or of childbearing potential who refuse to use a medically 
acceptable form of contraception; 
o Anemia (hemoglobin level <100g/L) or thrombocytopenia (platelet count <100 x 
109/L); 
o Patients considered not reliable such as those suffering from addictions or abusing 
alcohol. 
o Treatment with: ASA > 100 mg daily; ASA in combination with thienopyridines 
within 5 days before randomization; intravenous antiplatelets within 5 days before 
randomization; fibrinolytics within 10 days before randomization 
o Anticipated need for long-term treatment with a nonsteroidal antiinflammatory drug 
Source: (Lopes et al., 2010; Ezekowitz et al., 2009; The Executive Steering Committee, 2010) 
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